<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">944N6f3NJtJyn9pC7Dnh4yL</article-id>
      <article-id pub-id-type="other">00019</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010000500019</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09400519</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010000500019</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo de Revis&#227;o</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o normal</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Roscani</surname>
            <given-names>Meliza Goi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsubara</surname>
            <given-names>Luiz Shiguero</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsubara</surname>
            <given-names>Beatriz Bojikian</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Estadual Paulista</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina de Botucatu </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>05</month>
        <year>2010</year>
      </pub-date>
      <volume>94</volume>
      <issue>5</issue>
      <fpage>694</fpage>
      <lpage>702</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>07</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>04</day>
          <month>09</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>09</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o normal (ICFEN) &#233; uma s&#237;ndrome complexa que vem sendo largamente estudada, desde a &#250;ltima d&#233;cada. &#201; causada por disfun&#231;&#227;o ventricular diast&#243;lica evidenciada por m&#233;todos complementares, como estudo hemodin&#226;mico ou ecocardiograma, na presen&#231;a de fra&#231;&#227;o de eje&#231;&#227;o preservada. Acomete preferencialmente indiv&#237;duos mais idosos e com comorbidades, como hipertens&#227;o arterial sist&#234;mica, insufici&#234;ncia coronariana e obesidade. Os mecanismos fisiopatol&#243;gicos s&#227;o complexos e multifatoriais, envolvendo a rigidez passiva do mioc&#225;rdio, a geometria ventricular, a for&#231;a de conten&#231;&#227;o do peric&#225;rdio e a intera&#231;&#227;o entre os ventr&#237;culos. Os objetivos principais do tratamento s&#227;o reduzir a congest&#227;o venosa pulmonar, a frequ&#234;ncia card&#237;aca e controlar as comorbidades. Ainda n&#227;o h&#225; evid&#234;ncias fortes de que o uso de medica&#231;&#245;es espec&#237;ficas, como inibidores de enzima de convers&#227;o ou betabloqueadores, interfiram na mortalidade. Os fatores de pior progn&#243;stico incluem a idade avan&#231;ada, presen&#231;a de disfun&#231;&#227;o renal, diabete, classe funcional III e IV (NYHA) e est&#225;gio avan&#231;ado de disfun&#231;&#227;o diast&#243;lica, com padr&#227;o restritivo ao enchimento ventricular. Outro aspecto que vem ganhando espa&#231;o na literatura &#233; o questionamento do papel da disfun&#231;&#227;o sist&#243;lica nos quadros de ICFEN. Todos esses aspectos s&#227;o abordados detalhadamente na presente revis&#227;o.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>di&#225;stole</kwd>
        <kwd>cardiomegalia</kwd>
        <kwd>ecocardiografia</kwd>
        <kwd>complac&#234;ncia</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>22</day>
        <month>09</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO DE REVIS&#195;O</bold>
    </p>
    <p>
      <bold>Insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o normal</bold>
    </p>
    <p>
      <bold>Meliza Goi Roscani; Luiz Shiguero Matsubara; Beatriz Bojikian Matsubara</bold>
    </p>
    <p>Faculdade de Medicina de Botucatu - UNESP, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o normal (ICFEN) &#233; uma s&#237;ndrome complexa que vem sendo largamente estudada, desde a &#250;ltima d&#233;cada. &#201; causada por disfun&#231;&#227;o ventricular diast&#243;lica evidenciada por m&#233;todos complementares, como estudo hemodin&#226;mico ou ecocardiograma, na presen&#231;a de fra&#231;&#227;o de eje&#231;&#227;o preservada. Acomete preferencialmente indiv&#237;duos mais idosos e com comorbidades, como hipertens&#227;o arterial sist&#234;mica, insufici&#234;ncia coronariana e obesidade. Os mecanismos fisiopatol&#243;gicos s&#227;o complexos e multifatoriais, envolvendo a rigidez passiva do mioc&#225;rdio, a geometria ventricular, a for&#231;a de conten&#231;&#227;o do peric&#225;rdio e a intera&#231;&#227;o entre os ventr&#237;culos. Os objetivos principais do tratamento s&#227;o reduzir a congest&#227;o venosa pulmonar, a frequ&#234;ncia card&#237;aca e controlar as comorbidades. Ainda n&#227;o h&#225; evid&#234;ncias fortes de que o uso de medica&#231;&#245;es espec&#237;ficas, como inibidores de enzima de convers&#227;o ou betabloqueadores, interfiram na mortalidade. Os fatores de pior progn&#243;stico incluem a idade avan&#231;ada, presen&#231;a de disfun&#231;&#227;o renal, diabete, classe funcional III e IV (NYHA) e est&#225;gio avan&#231;ado de disfun&#231;&#227;o diast&#243;lica, com padr&#227;o restritivo ao enchimento ventricular. Outro aspecto que vem ganhando espa&#231;o na literatura &#233; o questionamento do papel da disfun&#231;&#227;o sist&#243;lica nos quadros de ICFEN. Todos esses aspectos s&#227;o abordados detalhadamente na presente revis&#227;o.</p>
    <p><bold>Palavras-chave: </bold> Insufici&#234;ncia card&#237;aca, di&#225;stole, cardiomegalia, ecocardiografia, complac&#234;ncia.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca (IC) &#233; uma s&#237;ndrome complexa caracterizada por intoler&#226;ncia aos exerc&#237;cios f&#237;sicos, reten&#231;&#227;o de l&#237;quidos e fen&#244;menos congestivos, e, ap&#243;s o in&#237;cio dos sintomas, apresenta altas taxas de morbimortalidade. Trata-se de uma condi&#231;&#227;o com preval&#234;ncia crescente no mundo e estima-se que, em 2025, haver&#225; cinco milh&#245;es de casos no Brasil<sup>1</sup>. O risco acumulado de desenvolver IC no decorrer de uma d&#233;cada &#233; maior na popula&#231;&#227;o idosa do que em jovens<sup>2</sup>. Portanto, nos idosos com sinais ou sintomas cl&#225;ssicos de IC, a intoler&#226;ncia aos esfor&#231;os f&#237;sicos frequentemente se deve ao aumento da press&#227;o no &#225;trio esquerdo, ainda que a fra&#231;&#227;o de eje&#231;&#227;o permane&#231;a nos limites da normalidade. Essa condi&#231;&#227;o corresponde &#224; insufici&#234;ncia card&#237;aca diast&#243;lica (ICD). A entidade vem sendo foco de discuss&#227;o na &#250;ltima d&#233;cada e v&#225;rios conceitos foram reformulados, justificando a presente revis&#227;o.</p>
    <p>
      <bold>Terminologia</bold>
    </p>
    <p>Existe controv&#233;rsia na literatura sobre qual a denomina&#231;&#227;o mais apropriada para essa condi&#231;&#227;o cl&#237;nica "IC diast&#243;lica" ou "IC com fun&#231;&#227;o sist&#243;lica preservada". Aqueles que defendem a denomina&#231;&#227;o de IC com fun&#231;&#227;o sist&#243;lica preservada referem que essa forma mais descritiva evita confus&#227;o ou diagn&#243;stico incorreto, tendo em vista que a disfun&#231;&#227;o diast&#243;lica est&#225; presente em quase todos os casos de IC<sup>3</sup>.</p>
    <p>Os autores que defendem a denomina&#231;&#227;o de IC diast&#243;lica referem que ao se especificar o termo "diast&#243;lica", j&#225; se subentende que est&#225; sendo exclu&#237;da disfun&#231;&#227;o sist&#243;lica significativa e o fen&#244;meno congestivo &#233; dependente da disfun&#231;&#227;o diast&#243;lica (DD). Referem tamb&#233;m que o termo insufici&#234;ncia card&#237;aca com fun&#231;&#227;o sist&#243;lica preservada n&#227;o permite a distin&#231;&#227;o dos casos de valvopatia mitral em que a fra&#231;&#227;o de eje&#231;&#227;o (FE) &#233; normal e a IC n&#227;o se deve &#224; disfun&#231;&#227;o diast&#243;lica<sup>4</sup>.</p>
    <p>Atualmente, v&#225;rios autores substitu&#237;ram o termo fun&#231;&#227;o sist&#243;lica preservada por FE normal, entendendo que pacientes com IC diast&#243;lica podem ter algum grau de disfun&#231;&#227;o sist&#243;lica. Na literatura, essas denomina&#231;&#245;es s&#227;o utilizadas como sin&#244;nimas. Nesta revis&#227;o, preferencialmente, ser&#225; utilizado o termo IC com FE normal, ou ICFEN, por ser mais descritivo.</p>
    <p>
      <bold>Aspectos hist&#243;ricos e conceitos</bold>
    </p>
    <p>Segundo Roelandt, a primeira associa&#231;&#227;o entre relaxamento mioc&#225;rdico e fun&#231;&#227;o ventricular foi descrita em 1923, por Yendell Handerson, o qual afirmou que o relaxamento mioc&#225;rdico era t&#227;o importante quanto a contra&#231;&#227;o<sup>5</sup>. Exemplificou que um paciente idoso, com relaxamento mioc&#225;rdico retardado, poderia apresentar intoler&#226;ncia aos esfor&#231;os f&#237;sicos. Portanto, era descrito o que viria a se constituir a insufici&#234;ncia card&#237;aca com FE normal (ICFEN).</p>
    <p>No entanto, o conceito somente recebeu aten&#231;&#227;o nos anos 60<sup>6</sup> e na d&#233;cada seguinte, com estudos associando a isquemia mioc&#225;rdica com a disfun&#231;&#227;o diast&#243;lica do ventr&#237;culo esquerdo (VE)<sup>7,8</sup>.</p>
    <p>Em 1984, Brutsaert descreveu sua teoria sobre o triplo controle do relaxamento mioc&#225;rdico<sup>9</sup>, o qual dependeria da pr&#233;-carga, da inativa&#231;&#227;o muscular e da uniformidade de inativa&#231;&#227;o no tempo e no espa&#231;o.</p>
    <p>Gaasch definiu o termo disfun&#231;&#227;o diast&#243;lica em 1994, como "incapacidade do cora&#231;&#227;o de acomodar o volume de sangue durante a di&#225;stole com baixas press&#245;es; o enchimento ventricular &#233; retardado ou incompleto e a press&#227;o atrial aumenta, causando congest&#227;o pulmonar ou sist&#234;mica"<sup>10</sup>. Dez anos mais tarde, em 2004, o mesmo autor<sup>11</sup> redefiniu a entidade, escrevendo: "A disfun&#231;&#227;o diast&#243;lica pode ocorrer independente da FE ser normal ou reduzida. Se o paciente com FE normal desenvolve intoler&#226;ncia ao esfor&#231;o, dispneia e congest&#227;o, &#233; preciso usar o termo Insufici&#234;ncia Card&#237;aca Diast&#243;lica."</p>
    <p>Pesquisadores argumentaram que a ICD seria, de fato, a manifesta&#231;&#227;o cl&#237;nica de disfun&#231;&#227;o sist&#243;lica transit&#243;ria, secund&#225;ria &#224; isquemia ou hipertens&#227;o. Para refutar essa argumenta&#231;&#227;o, Baicu e colaboradores avaliaram pacientes com diagn&#243;stico de ICD e indiv&#237;duos sem disfun&#231;&#227;o ventricular por meio de manometria do VE associada ao c&#225;lculo do volume ventricular<sup>12</sup>. Os pacientes com ICD apresentaram todos os &#237;ndices de fun&#231;&#227;o sist&#243;lica global e de contratilidade mioc&#225;rdica preservados. Os autores conclu&#237;ram que, mesmo na presen&#231;a de discretas altera&#231;&#245;es da fun&#231;&#227;o sist&#243;lica, o termo ICD &#233; aplic&#225;vel, tendo em vista a evidente contribui&#231;&#227;o da disfun&#231;&#227;o diast&#243;lica no quadro de IC.</p>
    <p>
      <bold>Epidemiologia</bold>
    </p>
    <p>Dentre os pacientes com a s&#237;ndrome cl&#237;nica de IC, a preval&#234;ncia de ICFEN varia amplamente nos diferentes estudos, de 40%-71%, com m&#233;dia de 56%<sup>13</sup>. Essa varia&#231;&#227;o se deve, provavelmente, &#224; defini&#231;&#227;o adotada para o termo "fun&#231;&#227;o sist&#243;lica preservada" e &#224;s caracter&#237;sticas da popula&#231;&#227;o estudada, como idade, ra&#231;a e preval&#234;ncia de sexo feminino. Por exemplo, dois estudos publicados em 2000, um desenvolvido na popula&#231;&#227;o americana e outro na popula&#231;&#227;o europeia, utilizaram tr&#234;s categorias de fun&#231;&#227;o sist&#243;lica: preservada, discretamente reduzida e moderada ou gravemente reduzida. No entanto, no estudo americano a fun&#231;&#227;o sist&#243;lica foi considerada preservada se FE <underline>&gt;</underline> 0,50 e correspondeu a 24% dos pacientes<sup>14</sup>; no estudo europeu a FE <underline>&gt;</underline> 0,45 foi considerada preservada e correspondeu a 38% dos pacientes<sup>15</sup>. Outro aspecto &#233; o fato de alguns estudos agruparem pacientes com FE normal ou discretamente reduzida<sup>16</sup>.</p>
    <p>Com rela&#231;&#227;o &#224; idade, sabe-se que a preval&#234;ncia da ICFEN est&#225; diretamente associada a essa vari&#225;vel<sup>4</sup>. Estudo populacional incluindo indiv&#237;duos com mais de 45 anos descreveu preval&#234;ncia de IC igual a 2,6%. Desses indiv&#237;duos, 41% apresentavam FE maior que 0,50<sup>17</sup>. Resultados semelhantes foram encontrados em publica&#231;&#245;es posteriores<sup>18-20</sup>. Em popula&#231;&#245;es de idosos com mais de 70 anos, a preval&#234;ncia pode ultrapassar 50%<sup>21</sup>. Finalmente, casu&#237;sticas de pacientes com IC e com predomin&#226;ncia do sexo feminino podem apresentar taxas de FE preservada com frequ&#234;ncias t&#227;o elevadas quanto 60%<sup>22</sup>.</p>
    <p>
      <bold>Fisiopatologia</bold>
    </p>
    <p>O enchimento ventricular na di&#225;stole &#233; definido pelas caracter&#237;sticas f&#237;sicas da c&#226;mara, que estabelecem as rela&#231;&#245;es entre press&#227;o e volume. Essas caracter&#237;sticas f&#237;sicas s&#227;o regidas pela complac&#234;ncia ventricular que descreve a raz&#227;o entre uma dada varia&#231;&#227;o de volume e sua correspondente varia&#231;&#227;o de press&#227;o<sup>23-27</sup>. Embora esses conceitos sejam aplic&#225;veis aos dois ventr&#237;culos, ser&#225; utilizado o ventr&#237;culo esquerdo como refer&#234;ncia para facilitar a compreens&#227;o.</p>
    <p>A complac&#234;ncia deve ser analisada, considerando-se um dado ventr&#237;culo, ao final do enchimento diast&#243;lico, ap&#243;s a contra&#231;&#227;o atrial, quando todos os fen&#244;menos ativos da di&#225;stole, teoricamente, j&#225; se completaram (<xref ref-type="fig" rid="f1">Figura 1</xref>). Nesse momento particular do ciclo card&#237;aco, se o ventr&#237;culo opera em diferentes condi&#231;&#245;es de carga, os pontos de associa&#231;&#227;o press&#227;o-volume descrevem uma curva caracter&#237;stica no plano cartesiano, t&#237;pica de uma fun&#231;&#227;o exponencial.</p>
    <fig id="f1">
      <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf01.jpg"/></fig>
    <p>A primeira implica&#231;&#227;o cl&#237;nica dessa caracter&#237;stica &#233; que em um dado ventr&#237;culo contendo pouco volume, aumentos adicionais expressivos de volumes s&#227;o tolerados, sem varia&#231;&#227;o da press&#227;o. No entanto, ap&#243;s um certo limite, pequenos acr&#233;scimos de volume causam varia&#231;&#245;es importantes da press&#227;o diast&#243;lica. Isto &#233;, um mesmo ventr&#237;culo pode apresentar complac&#234;ncia vari&#225;vel, dependendo do volume em que opera<sup>25</sup>.</p>
    <p>A segunda implica&#231;&#227;o &#233; que ventr&#237;culos pequenos suportam volumes menores, enquanto grandes ventr&#237;culos podem conter volumes maiores com baixa press&#227;o. A <xref ref-type="fig" rid="f2">Figura 2</xref> ilustra de forma esquem&#225;tica os desvios da curva de complac&#234;ncia nas situa&#231;&#245;es patol&#243;gicas. Na hipertrofia conc&#234;ntrica, por exemplo, ocorrem varia&#231;&#245;es mais acentuadas da press&#227;o para uma dada varia&#231;&#227;o de volume, mesmo dentro dos limites considerados normais. Nesses casos, o paciente &#233; propenso a desenvolver congest&#227;o venosa, ainda que a FE esteja preservada. Ao contr&#225;rio, nas c&#226;maras dilatadas, quando a curva est&#225; desviada para a direita, a press&#227;o diast&#243;lica atingir&#225; valores elevados somente quando houver excesso de volume. &#201; o que ocorre nas disfun&#231;&#245;es sist&#243;licas, quando o volume residual na cavidade &#233; aumentado<sup>23,25</sup>.</p>
    <fig id="f2">
      <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf02.jpg"/></fig>
    <p>A di&#225;stole compreende quatro fases: relaxamento isovolum&#233;trico, enchimento ventricular r&#225;pido, di&#225;stase e contra&#231;&#227;o atrial. Durante o relaxamento isovolum&#233;trico, n&#227;o h&#225; enchimento ventricular. A fase de enchimento r&#225;pido vai de 70% a 80% do enchimento ventricular total, em indiv&#237;duos normais e depende diretamente do gradiente de press&#227;o atrioventricular. A di&#225;stase &#233; a fase em que as press&#245;es do &#225;trio e do ventr&#237;culo est&#227;o praticamente iguais e o fluxo transvalvar mitral corresponde a apenas 5% do fluxo total. A di&#225;stase poderia ser entendida como a reserva funcional que garante o enchimento ventricular, apesar de varia&#231;&#245;es da frequ&#234;ncia card&#237;aca. Isto &#233;, havendo taquicardia, o per&#237;odo a ser consumido seria a di&#225;stase. Assim, dentro de certos limites, o enchimento n&#227;o seria prejudicado. A contra&#231;&#227;o atrial contribui com 15% a 25% do volume diast&#243;lico e, em situa&#231;&#245;es fisiol&#243;gicas, cursa com a manuten&#231;&#227;o da press&#227;o atrial m&#233;dia.</p>
    <p>Nos limites fisiol&#243;gicos de varia&#231;&#227;o da frequ&#234;ncia card&#237;aca, e considerando essas quatro fases da di&#225;stole, os fatores que afetam a complac&#234;ncia ventricular e est&#227;o associados a ICFEN s&#227;o: rigidez passiva do mioc&#225;rdio, geometria ventricular, for&#231;a de conten&#231;&#227;o do peric&#225;rdio e intera&#231;&#227;o entre os ventr&#237;culos.</p>
    <p>
      <bold>Rigidez passiva mioc&#225;rdica</bold>
    </p>
    <p>Rigidez passiva do mioc&#225;rdio tamb&#233;m corresponde a uma propriedade mec&#226;nica e descreve a for&#231;a necess&#225;ria a ser aplicada ao m&#250;sculo para produzir uma dada deforma&#231;&#227;o. Portanto, segundo esse conceito f&#237;sico, o mioc&#225;rdio &#233; considerado um material inerte, com caracter&#237;stica f&#237;sica que depende intrinsecamente da sua composi&#231;&#227;o e n&#227;o do processo ativo do relaxamento<sup>27</sup>.</p>
    <p>Por&#233;m, biologicamente, o relaxamento alterado pode aumentar a rigidez passiva do mioc&#225;rdio, na medida em que n&#227;o se completa. Isto &#233;, ao final da di&#225;stole, o m&#250;sculo ainda parcialmente contra&#237;do, comporta-se como um material mais r&#237;gido. Outro aspecto relevante &#233; o caso de relaxamento mioc&#225;rdico apenas retardado. Teoricamente, essa altera&#231;&#227;o n&#227;o deveria prejudicar a complac&#234;ncia ventricular e nem causar IC. No entanto, havendo taquicardia e supress&#227;o da di&#225;stase, o relaxamento mais lento pode se comportar como um relaxamento incompleto, e o enchimento ventricular ocorrer&#225; com press&#227;o elevada, podendo causar fen&#244;menos congestivos. Essa &#233; uma das explica&#231;&#245;es do porqu&#234; pacientes com ICFEN n&#227;o toleram eleva&#231;&#245;es da frequ&#234;ncia card&#237;aca.</p>
    <p>De modo simplificado, pode-se afirmar que a rigidez passiva mioc&#225;rdica depende do relaxamento e da composi&#231;&#227;o do m&#250;sculo.</p>
    <p>
      <bold>Relaxamento mioc&#225;rdico</bold>
    </p>
    <p>O relaxamento mioc&#225;rdico requer gasto de energia e tem in&#237;cio durante a fase final da eje&#231;&#227;o sist&#243;lica. Esse processo influencia principalmente as fases iniciais da di&#225;stole. Em cora&#231;&#245;es normais, mesmo durante o exerc&#237;cio f&#237;sico, o processo se completa nesse per&#237;odo. A libera&#231;&#227;o de catecolaminas acelera o relaxamento das fibras mioc&#225;rdicas, mantendo a baixa press&#227;o diast&#243;lica, apesar da taquicardia e do aumento do retorno venoso. &#201; o relaxamento mioc&#225;rdico que gera o gradiente de press&#227;o entre o &#225;trio esquerdo (AE) e o VE, sem eleva&#231;&#227;o adicional da press&#227;o atrial esquerda, prevenindo a congest&#227;o pulmonar<sup>24</sup>.</p>
    <p>O relaxamento depende principalmente da oferta de ATP e da homeostase do c&#225;lcio intracelular. A fun&#231;&#227;o inadequada de v&#225;rias prote&#237;nas envolvidas na homeostase do c&#225;lcio tamb&#233;m pode afetar profundamente o processo de relaxamento<sup>28</sup>.</p>
    <p>Nos casos de atraso no relaxamento do VE nos quais ainda h&#225; manuten&#231;&#227;o da press&#227;o atrial esquerda, ocorre a diminui&#231;&#227;o do gradiente de press&#227;o atrioventricular e o prolongamento do tempo de enchimento r&#225;pido. Como consequ&#234;ncia, h&#225; redu&#231;&#227;o do enchimento ventricular na fase inicial da di&#225;stole. Em est&#225;gios mais avan&#231;ados, quando al&#233;m das altera&#231;&#245;es do relaxamento mioc&#225;rdico h&#225; redu&#231;&#227;o da complac&#234;ncia ventricular, as press&#245;es nas duas c&#226;maras, &#225;trio e ventr&#237;culo, crescem e os pacientes podem apresentar algum grau de intoler&#226;ncia aos esfor&#231;os. Altera&#231;&#245;es mais graves, como o relaxamento incompleto e complac&#234;ncia reduzida, levam ao aumento da press&#227;o diast&#243;lica, a um ponto de restringir o esvaziamento atrial. Nessa condi&#231;&#227;o, em geral, h&#225; sinais t&#237;picos de IC esquerda, como dispneia aos pequenos esfor&#231;os ou em repouso.</p>
    <p>
      <bold>Composi&#231;&#227;o do mioc&#225;rdio</bold>
    </p>
    <p>Os mi&#243;citos ocupam 70% do volume do m&#250;sculo card&#237;aco. Al&#233;m deles, existem os vasos, os fibroblastos e uma rede fibrilar de col&#225;geno, de estrutura bastante complexa. Embora o col&#225;geno ocupe apenas de 4%-6% do volume do m&#250;sculo, sua alta rigidez passiva, semelhante &#224; do a&#231;o, faz com que pequenas varia&#231;&#245;es em sua concentra&#231;&#227;o produzam efeitos expressivos na rigidez passiva do mioc&#225;rdio<sup>29</sup>.</p>
    <p>Nas agress&#245;es card&#237;acas, os fatores mec&#226;nicos levam &#224; ativa&#231;&#227;o secund&#225;ria de fatores bioqu&#237;micos (ativa&#231;&#227;o neuro-hormonal e libera&#231;&#227;o de citocinas pr&#243;-inflamat&#243;rias). Dentre os v&#225;rios efeitos dessas modifica&#231;&#245;es, est&#227;o a perda de mi&#243;citos, a produ&#231;&#227;o de inibidores das metaloproteases tissulares pelo endot&#233;lio e a produ&#231;&#227;o de col&#225;geno e colagenases pelos fibroblastos. A intera&#231;&#227;o desses fatores determina a concentra&#231;&#227;o de col&#225;geno no processo de remodela&#231;&#227;o mioc&#225;rdica</p>
    <p>Em se tratando de composi&#231;&#227;o do mioc&#225;rdio, n&#227;o &#233; s&#243; a altera&#231;&#227;o do col&#225;geno que promove a disfun&#231;&#227;o diast&#243;lica. A hipertrofia mioc&#225;rdica &#233; outra vari&#225;vel de import&#226;ncia, que marca a evolu&#231;&#227;o da agress&#227;o card&#237;aca inicial &#224; insufici&#234;ncia card&#237;aca e morte cardiovascular (CV). Nos casos de hipertrofia conc&#234;ntrica, h&#225; redu&#231;&#227;o da reserva coronariana e aumento do risco de isquemia mioc&#225;rdica, independentemente da presen&#231;a de doen&#231;a ateroscler&#243;tica coronariana, causando os dist&#250;rbios de relaxamento j&#225; discutidos. A pr&#243;pria mudan&#231;a da geometria do ventr&#237;culo poder&#225; se constituir em fator independente de altera&#231;&#227;o da complac&#234;ncia e disfun&#231;&#227;o diast&#243;lica<sup>30</sup>.</p>
    <p>
      <bold>Geometria do ventr&#237;culo</bold>
    </p>
    <p>A hipertrofia exc&#234;ntrica (multiplica&#231;&#227;o em s&#233;rie dos sarc&#244;meros) resulta em dilata&#231;&#227;o da c&#226;mara ventricular proporcionando maior toler&#226;ncia ao volume que chega aos ventr&#237;culos. Nesse caso, os fen&#244;menos congestivos somente aparecem quando o volume dentro da c&#226;mara excede determinado limite. Isto &#233;, a congest&#227;o e a disfun&#231;&#227;o diast&#243;lica s&#227;o secund&#225;rias &#224; disfun&#231;&#227;o sist&#243;lica. &#201; importante compreender que o ventr&#237;culo dilatado pode se comportar como c&#226;mara complacente, ainda que o mioc&#225;rdio apresente concentra&#231;&#227;o anormal de fibrose e rigidez passiva aumentada.</p>
    <p>A c&#226;mara com geometria conc&#234;ntrica tem comportamento diferente porque o ventr&#237;culo &#233; mais propenso &#224; disfun&#231;&#227;o diast&#243;lica, independentemente da presen&#231;a ou da aus&#234;ncia de hipertrofia ventricular esquerda (HVE). Do ponto de vista f&#237;sico, &#233; f&#225;cil entender que uma c&#226;mara de raio pequeno e com paredes grossas apresente maior resist&#234;ncia ao estiramento. No entanto, a mudan&#231;a de geometria &#233; mais complexa e extrapola a caracter&#237;stica f&#237;sica. Geometria conc&#234;ntrica est&#225; associada a mudan&#231;as metab&#243;licas expressivas, ativa&#231;&#227;o funcional e mudan&#231;a do perfil de express&#227;o g&#234;nica do m&#250;sculo<sup>31</sup>. Todos esses fatores atuam sinergicamente no sentido de promover a disfun&#231;&#227;o mioc&#225;rdica.</p>
    <p>
      <bold>For&#231;a de conten&#231;&#227;o do peric&#225;rdio</bold>
    </p>
    <p>O cora&#231;&#227;o est&#225; contido dentro de uma estrutura r&#237;gida composta por col&#225;geno que &#233; o saco peric&#225;rdico. O peric&#225;rdio tem grande capacidade de adapta&#231;&#227;o em situa&#231;&#245;es de dilata&#231;&#227;o cr&#244;nica ventricular, quando h&#225; aumento de complac&#234;ncia.</p>
    <p>Ao contr&#225;rio, nas situa&#231;&#245;es de dilata&#231;&#227;o aguda de qualquer dos ventr&#237;culos, como em alguns casos de insufici&#234;ncia mitral e cor pulmonale, o aumento da press&#227;o diast&#243;lica e a eventual congest&#227;o pulmonar podem apresentar componente da for&#231;a de conten&#231;&#227;o imposta pelo saco peric&#225;rdico.</p>
    <p>
      <bold>Intera&#231;&#227;o entre os ventr&#237;culos</bold>
    </p>
    <p>Aumentos agudos do volume e da press&#227;o de um dos ventr&#237;culos podem afetar a complac&#234;ncia do outro ventr&#237;culo. No entanto, essa intera&#231;&#227;o &#233; muito atenuada na aus&#234;ncia do peric&#225;rdio.</p>
    <p>
      <bold>Apresenta&#231;&#227;o cl&#237;nica e diagn&#243;stico</bold>
    </p>
    <p>A apresenta&#231;&#227;o cl&#237;nica &#233; semelhante &#224; da insufici&#234;ncia card&#237;aca sist&#243;lica. &#201; descrito que, na ICFEN, o quadro de dispneia se instala mais agudamente e a resposta &#224;s interven&#231;&#245;es tamb&#233;m &#233; mais r&#225;pida<sup>32,33</sup>. Em estudo europeu que incluiu pacientes internados com IC, foi observado que a preval&#234;ncia de ICFEN foi de 40%. Essa entidade foi associada de forma significante e independente com o sexo feminino, idade avan&#231;ada e presen&#231;a de fibrila&#231;&#227;o atrial (FA). A insufici&#234;ncia card&#237;aca sist&#243;lica foi associada com classe funcional (NYHA) mais avan&#231;ada, cardiomegalia, presen&#231;a de terceira bulha, edema agudo de pulm&#227;o e bloqueio de ramo esquerdo<sup>32</sup>. O <xref ref-type="fig" rid="q1">Quadro 1</xref> mostra as diferen&#231;as entre ICFEN e IC com FE reduzida.</p>
    <fig id="q1">
      <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf03.jpg"/></fig>
    <p>A insufici&#234;ncia card&#237;aca secund&#225;ria &#224; DD &#233; entendida hoje como a entidade das comorbidades. V&#225;rios estudos mostraram que pacientes com ICFEN t&#234;m hipertens&#227;o arterial (HAS), isquemia mioc&#225;rdica, diabetes melitus (DM), obesidade e disfun&#231;&#227;o tireoideana. A associa&#231;&#227;o com doen&#231;as intr&#237;nsecas do cora&#231;&#227;o &#233; menos frequente<sup>34,35</sup>.</p>
    <p>Os &#237;ndices capazes de quantificar diretamente a fun&#231;&#227;o diast&#243;lica s&#227;o obtidos de forma invasiva. O primeiro deles &#233; a constante de tau, medida largamente utilizada da taxa do relaxamento do ventr&#237;culo esquerdo<sup>36,37</sup>. O segundo indicador direto &#233; a medida da complac&#234;ncia ventricular, que requer o registro simult&#226;neo da press&#227;o e do volume da c&#226;mara<sup>12</sup>. O ventr&#237;culo menos complacente &#233; aquele que apresenta maior eleva&#231;&#227;o da press&#227;o para uma dada varia&#231;&#227;o de volume. &#201; claro que os dois &#237;ndices s&#227;o invi&#225;veis para uso rotineiro na pr&#225;tica cl&#237;nica.</p>
    <p>Os marcadores dispon&#237;veis na pr&#225;tica cl&#237;nica refletem, de fato, um conjunto de vari&#225;veis que indiretamente avaliam a fun&#231;&#227;o diast&#243;lica. Embora os indicadores mais utilizados para a avalia&#231;&#227;o da fun&#231;&#227;o diast&#243;lica sejam obtidos por meio do ecocardiograma, o diagn&#243;stico deve seguir as recomenda&#231;&#245;es da Sociedade Brasileira de Cardiologia para o diagn&#243;stico de IC de qualquer etiologia<sup>38</sup>. Isto &#233;, diante da suspeita cl&#237;nica de IC, faz-se necess&#225;ria a realiza&#231;&#227;o do eletrocardiograma, RX de t&#243;rax e, se poss&#237;vel, a dosagem do BNP. Se forem detectadas altera&#231;&#245;es nesses exames laboratoriais, solicita-se o ecocardiograma que permitir&#225; confirmar ou descartar o diagn&#243;stico de ICFEN. Vale destacar, pela facilidade de obten&#231;&#227;o do exame, que o RX de t&#243;rax, embora n&#227;o espec&#237;fico, pode auxiliar na suspei&#231;&#227;o do diagn&#243;stico. Isto &#233;, diante de um caso de IC, a presen&#231;a de cardiomegalia aumenta a chance de disfun&#231;&#227;o sist&#243;lica. Ao contr&#225;rio, se a &#225;rea card&#237;aca for normal, aumenta a probabilidade de ICFEN.</p>
    <p>O ecocardiograma tem maior acur&#225;cia e permite o diagn&#243;stico de altera&#231;&#245;es estruturais, como a hipertrofia e &#225;reas de hipocinesias, frequentemente associadas com disfun&#231;&#227;o diast&#243;lica. A hipocinesia regional &#233; fortemente sugestiva de isquemia mioc&#225;rdica, com os efeitos delet&#233;rios sobre o relaxamento, explicando a associa&#231;&#227;o. Al&#233;m disso, o Doppler puls&#225;til permite a an&#225;lise do fluxo diast&#243;lico transmitral, da qual derivam os &#237;ndices prim&#225;rios de fun&#231;&#227;o e a estratifica&#231;&#227;o da gravidade da disfun&#231;&#227;o<sup>39</sup>. Como descrito anteriormente, esse fluxo depende do gradiente de press&#227;o transvalvar. Em condi&#231;&#245;es normais, esse gradiente &#233; m&#225;ximo imediatamente ap&#243;s a abertura da valva mitral, tendo em vista a plenitude de volume do &#225;trio esquerdo e a baixa press&#227;o intraventricular, devido ao relaxamento mioc&#225;rdico e ao pequeno volume residual na c&#226;mara. Nesse momento, a velocidade de fluxo &#233; m&#225;xima, constituindo a onda E.</p>
    <p>Segue-se o per&#237;odo de gradiente transvalvar reduzido, com fluxo quase nulo (di&#225;stase). A contra&#231;&#227;o atrial gera um novo gradiente e fluxo, correspondente &#224; onda A. A raz&#227;o E/A, um dos &#237;ndices prim&#225;rios para o estudo da di&#225;stole, permanece 1 (<xref ref-type="fig" rid="f3">Figura 3</xref>, <xref ref-type="fig" rid="f3">A</xref>). Estando o relaxamento mioc&#225;rdico prejudicado, h&#225; redu&#231;&#227;o do gradiente transvalvar, no in&#237;cio da di&#225;stole, com diminui&#231;&#227;o da onda E. A consequ&#234;ncia &#233; o preju&#237;zo do esvaziamento atrial; a contra&#231;&#227;o atrial &#233; mais vigorosa e a onda A cresce, reduzindo a raz&#227;o E/A (<xref ref-type="fig" rid="f3">Figura 3</xref>, <xref ref-type="fig" rid="f3">B</xref>). Esse padr&#227;o de fluxo &#233; caracter&#237;stico de DD leve ou grau I. Havendo preju&#237;zo adicional da fun&#231;&#227;o, a press&#227;o no &#225;trio esquerdo cresce, recompondo os gradientes de press&#227;o transvalvar durante a di&#225;stole, ainda que em n&#237;veis maiores de press&#227;o e na presen&#231;a de sintoma de intoler&#226;ncia aos esfor&#231;os. Nesse est&#225;gio, a DD &#233; de grau II ou moderado (<xref ref-type="fig" rid="f3">Figura 3</xref>, <xref ref-type="fig" rid="f3">C</xref>).</p>
    <p content-type="html"><fig id="f3"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/944N6f3NJtJyn9pC7Dnh4yL/75dfcf3954ade488335bade82d41b48553b56b99.jpg"/><graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf04.jpg"/></fig>&#13;
</p>
    <p>Nos pacientes em que a press&#227;o diast&#243;lica do VE &#233; alta suficiente para restringir o fluxo transvalvar durante a contra&#231;&#227;o atrial, a press&#227;o elevada do AE permite apenas um fluxo diast&#243;lico inicial de alta velocidade e curta dura&#231;&#227;o, sendo a velocidade de fluxo no final da di&#225;stole marcadamente reduzida (<xref ref-type="fig" rid="f3">Figura 3</xref>, <xref ref-type="fig" rid="f3">D</xref>). Esse padr&#227;o, chamado de restritivo ou grau III, &#233; grave e causa intoler&#226;ncia aos esfor&#231;os leves. Quando a manobra de Valsalva n&#227;o alivia essa altera&#231;&#227;o, define-se a DD grau IV, tamb&#233;m grave. Os outros dois indicadores prim&#225;rios derivados do Doppler puls&#225;til s&#227;o o tempo de desacelera&#231;&#227;o da onda E e o tempo de relaxamento isovolum&#233;trico.</p>
    <p>A an&#225;lise do fluxo nas veias pulmonares por meio do Doppler puls&#225;til permite a avalia&#231;&#227;o indireta da press&#227;o atrial que, na aus&#234;ncia de valvopatia mitral, corresponde &#224; press&#227;o diast&#243;lica do VE. Resumidamente, as press&#245;es normais no AE permitem fluxo constante a partir das veias pulmonares, exceto durante a contra&#231;&#227;o atrial, quando h&#225; pequeno fluxo reverso. Quando esse padr&#227;o se altera, &#233; poss&#237;vel diagnosticar disfun&#231;&#227;o diast&#243;lica.</p>
    <p>Mais recentemente, foram inclu&#237;dos na avalia&#231;&#227;o da fun&#231;&#227;o diast&#243;lica outros &#237;ndices valiosos, como as medidas da velocidade de movimenta&#231;&#227;o do tecido anular mitral (Doppler tissular) e a estimativa do volume e da fra&#231;&#227;o de esvaziamento do AE. Atualmente, essas vari&#225;veis, juntamente com a avalia&#231;&#227;o do volume ventricular e da massa mioc&#225;rdica, s&#227;o consideradas fundamentais para a defini&#231;&#227;o do diagn&#243;stico e da estratifica&#231;&#227;o de gravidade da ICFEN<sup>15,39</sup>. &#201; importante ressaltar que as recomenda&#231;&#245;es europeia, americana e brasileira sobre esse tema incorporaram as altera&#231;&#245;es fisiol&#243;gicas pr&#243;prias do envelhecimento nos valores dos &#237;ndices prim&#225;rios e daqueles derivados do Doppler tissular<sup>14,15,38</sup>. Com isso, a acur&#225;cia do m&#233;todo em identificar indiv&#237;duos de maior risco dever&#225; ser melhorada.</p>
    <p>Um aspecto relevante a ser considerado pelo cl&#237;nico que assiste o paciente com ICFEN &#233; a labilidade de v&#225;rios &#237;ndices de fun&#231;&#227;o diast&#243;lica em rela&#231;&#227;o &#224; atividade f&#237;sica. Uma vez que os exames s&#227;o efetuados com os pacientes em repouso, pode haver discrep&#226;ncia entre a intensidade da dispneia de esfor&#231;o e o resultado da estratifica&#231;&#227;o do grau da DD. Nesses casos, a avalia&#231;&#227;o ecocardiogr&#225;fica pode ser realizada imediatamente ap&#243;s esfor&#231;o f&#237;sico<sup>39</sup>. A discuss&#227;o detalhada e t&#233;cnica sobre esses indicadores interessa mais ao especialista em ecocardiografia e n&#227;o &#233; o foco da presente revis&#227;o. Entretanto, &#233; preciso refor&#231;ar o fato de que permanece em debate na literatura a confiabilidade dos &#237;ndices n&#227;o invasivos, especialmente a raz&#227;o velocidade de fluxo/velocidade de movimenta&#231;&#227;o do anel mitral, para estimar a press&#227;o de enchimento do ventr&#237;culo esquerdo<sup>40-42</sup>.</p>
    <p>O diagn&#243;stico definitivo de disfun&#231;&#227;o diast&#243;lica requer tr&#234;s crit&#233;rios segundo o conceito atual<sup>15</sup>: dois maiores e um confirmat&#243;rio. A evid&#234;ncia inequ&#237;voca de DD e a evid&#234;ncia objetiva de fun&#231;&#227;o sist&#243;lica preservada (FE maior que 0,50 nas 72h de agudiza&#231;&#227;o da IC) constituem crit&#233;rios maiores. A evid&#234;ncia objetiva de ICD constitui crit&#233;rio confirmat&#243;rio. A avalia&#231;&#227;o objetiva de DD poderia ser derivada do ecocardiograma, segundo Paulus e cols.<sup>15</sup>, ou de medida direta invasiva, segundo Vasan e Levy<sup>43</sup>.</p>
    <p>Em 2001, Zile e cols.<sup>44</sup> avaliaram, por meio de cateterismo card&#237;aco, a fun&#231;&#227;o diast&#243;lica de pacientes com ICD e verificaram que todos apresentavam DD. Zile e cols.<sup>44</sup> questionaram a necessidade desse terceiro crit&#233;rio. Em 2005, Yturralde e Gaasch<sup>45</sup> propuseram que os dois primeiros crit&#233;rios fossem considerados maiores, desde que o tamanho do VE fosse normal e que o terceiro crit&#233;rio fosse apenas confirmat&#243;rio, associado &#224; presen&#231;a de HVE e AE aumentado, na aus&#234;ncia de valvopatia mitral e FA<sup>45</sup>.</p>
    <p>De fato, esses sinais indiretos est&#227;o sendo valorizados como marcadores de DD. Pritchett e cols.<sup>46</sup> utilizaram os valores de volume AE em mais de 2.000 indiv&#237;duos, com idade igual ou superior a 45 anos, inclu&#237;dos no Estudo do Condado de Olmsted, e observaram que essa vari&#225;vel tem valor progn&#243;stico na predi&#231;&#227;o de mortalidade em 5 anos<sup>46</sup>. Lester e cols.<sup>47</sup> defenderam a posi&#231;&#227;o de que o volume do AE estaria para a DD como a hemoglobina glicosilada est&#225; para o DM.</p>
    <p>No entanto, podem ocorrer muitas dificuldades no diagn&#243;stico, como a impossibilidade de se obter o ecocardiograma, ou sintomas inespec&#237;ficos e sinais pouco evidentes. Frequentemente, os pacientes t&#234;m doen&#231;a pulmonar associada ou s&#227;o obesos; s&#227;o idosos com v&#225;rias comorbidades ou com dificuldades de comunica&#231;&#227;o. Enfim, existe uma s&#233;rie de circunst&#226;ncias cl&#237;nicas que impede a associa&#231;&#227;o direta entre uma queixa de limita&#231;&#227;o f&#237;sica ou dispneia com o diagn&#243;stico de IC.</p>
    <p>Nesses casos, um marcador laboratorial que se apresenta e que pode ser &#250;til &#233; o n&#237;vel plasm&#225;tico do BNP (<italic>brain natriuretic factor</italic>). Esse pept&#237;deo natriur&#233;tico &#233; estocado no mioc&#225;rdio ventricular, sendo liberado quando a parede sofre estiramento. Apresenta menor influ&#234;ncia das varia&#231;&#245;es da press&#227;o no &#225;trio e, por isso, reflete melhor disfun&#231;&#227;o ventricular do que o pept&#237;deo natriur&#233;tico atrial.</p>
    <p>Muitos estudos mostraram a utilidade do BNP como marcador diagn&#243;stico e progn&#243;stico na IC sist&#243;lica<sup>48,49</sup>. Na IC diast&#243;lica, as evid&#234;ncias n&#227;o s&#227;o t&#227;o contundentes, mas come&#231;am a aparecer. O n&#237;vel de BNP com maior acur&#225;cia para detectar disfun&#231;&#227;o diast&#243;lica &#233; 60-90 pg/ml<sup>50</sup>. Al&#233;m disso, o n&#237;vel de BNP &#233; tanto maior quanto mais grave a disfun&#231;&#227;o e cresce ainda mais na presen&#231;a de sinais cl&#237;nicos de IC. O consenso atual entende que o BNP ainda &#233; mais importante para descartar a origem card&#237;aca em pacientes atendidos com dispneia em repouso<sup>38</sup>.</p>
    <p>
      <bold>Tratamento</bold>
    </p>
    <p>Poucos estudos avaliaram desfechos cl&#237;nicos em pacientes com ICD e que foram tratados com diferentes classes de drogas. E o fato &#233; que nenhum deles mostrou mudan&#231;a na hist&#243;ria natural da s&#237;ndrome.</p>
    <p>O primeiro grande estudo, e bem conhecido, foi o CHARM-preserved<sup>51</sup>, publicado em 2003 e destinado a avaliar o efeito do candesartan em 3.025 pacientes com IC e FE maior do que 40%. A popula&#231;&#227;o que compunha o estudo era predominantemente masculina e com faixa et&#225;ria inferior a que mais apresenta ICD. Nesse estudo, n&#227;o houve redu&#231;&#227;o da mortalidade, embora o n&#250;mero de interna&#231;&#245;es por IC tenha sido significantemente menor.</p>
    <p>O estudo PEP-CHF<sup>52</sup> incluiu pacientes mais idosos, com idade acima de 70 anos e FE &gt; 45%, e falhou em mostrar redu&#231;&#227;o na mortalidade com o uso prolongado de perindopril. Outros estudos tamb&#233;m n&#227;o evidenciaram efeitos relevantes com o uso do nebivolol<sup>53</sup> e com digoxina<sup>54</sup>. Recentemente, o estudo I PRESERVED, incluindo pacientes com mais de 60 anos e FE &gt; 60%, mostrou que o ibersartan n&#227;o diminuiu o risco do desfecho composto morte e hospitaliza&#231;&#227;o por causa cardiovascular<sup>55</sup>. O estudo TOPCAT, com t&#233;rmino previsto para 2011, pretende avaliar os efeitos da espironolactona nos desfechos cl&#237;nicos de 4.500 pacientes com fun&#231;&#227;o sist&#243;lica preservada.</p>
    <p>Nesse contexto, atualmente os objetivos principais no tratamento da ICFEN s&#227;o controlar os sintomas pela redu&#231;&#227;o da congest&#227;o venosa e da frequ&#234;ncia card&#237;aca. O controle do ritmo tamb&#233;m &#233; considerado v&#225;lido em pacientes selecionados, seja por meio de cardiovers&#227;o el&#233;trica e/ou qu&#237;mica, ou marca-passo sequencial.</p>
    <p>Outras metas a serem atingidas s&#227;o os controles das comorbidades associadas com DD, como tratamento da isquemia mioc&#225;rdica e da HAS, preven&#231;&#227;o e revers&#227;o da hipertrofia ventricular esquerda, atenua&#231;&#227;o ou preven&#231;&#227;o de fibrose mioc&#225;rdica.</p>
    <p>&#201; preciso lembrar que esses pacientes com DD s&#227;o tipicamente idosos e com cavidade ventricular de tamanho normal. Portanto, medidas como diur&#233;ticos e vasodilatadores podem ter efeito desproporcional na PA. Os cuidados espec&#237;ficos incluem a monitora&#231;&#227;o da press&#227;o arterial, da fun&#231;&#227;o renal e de sinais de hipofluxo cerebral. Incluem tamb&#233;m estimular a ader&#234;ncia ao tratamento e mudan&#231;as de h&#225;bitos de vida (alimenta&#231;&#227;o, atividade f&#237;sica e tabagismo, principalmente), tendo em vista que esses pacientes s&#227;o medicados simultaneamente com v&#225;rias classes de drogas.</p>
    <p>Em idosos, a conduta deve obedecer a alguns crit&#233;rios especiais. Orienta-se iniciar com uma classe de droga e ir adicionando outras classes, sempre uma por vez. N&#227;o existem evid&#234;ncias de que a dose alvo de cada classe deva ser atingida, como ocorre na IC sist&#243;lica.</p>
    <p>Assim, recomenda-se:</p>
    <p>&#149; Iniciar diur&#233;ticos e betabloqueadores com cautela;</p>
    <p>&#149; Se a IC persistir, adicionar inibidor de enzima de convers&#227;o da angiotensina (IECA), ou bloqueador do receptor de angiotensina (BRA), se houver intoler&#226;ncia a IECA;</p>
    <p>&#149; Adicionar dinitrato de isossorbida e hidralazina, se necess&#225;rio;</p>
    <p>&#149; Adicionar antagonistas dos canais de c&#225;lcio, se necess&#225;rio;</p>
    <p>&#149; Evitar o uso de digit&#225;licos, na aus&#234;ncia de FA.</p>
    <p>O <xref ref-type="fig" rid="fig19q2">Quadro 2</xref> resume as principais op&#231;&#245;es terap&#234;uticas e respectivos n&#237;veis de evid&#234;ncia nos casos de ICFEN, segundo a III Diretriz Brasileira de Insufici&#234;ncia Card&#237;aca Cr&#244;nica<sup>38</sup>. Observar que os n&#237;veis de evid&#234;ncia para cada op&#231;&#227;o terap&#234;utica ainda n&#227;o s&#227;o elevados. Portanto, nesses pacientes, &#233; importante a individualiza&#231;&#227;o do tratamento.</p>
    <p content-type="asset">
      <fig id="fig19q2">
        <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf05.jpg"/></fig>
    </p>
    <p>
      <bold>Progn&#243;stico</bold>
    </p>
    <p>Estudo de pacientes com ICFEN mostrou que a sobrevida em 1, 3 e 5 anos foi, respectivamente, 84%, 67% e 51%<sup>32</sup>. Em outro estudo, o impacto da gravidade da DD foi avaliado em 2.042 adultos com mais de 45 anos, sendo 95% assintom&#225;ticos. Observou-se que a mortalidade foi significativamente maior naqueles com ecocardiograma evidenciando DD graus II e III<sup>17</sup>. Esses resultados foram semelhantes aos descritos por Pritchett e cols.<sup>46</sup>. Al&#233;m disso, esses autores observaram que o volume do AE apresentou valor progn&#243;stico semelhante ao da gravidade da DD. Em pacientes com insufici&#234;ncia coronariana cr&#244;nica, a mortalidade cardiovascular em tr&#234;s anos foi significativamente maior (6%) nos casos com DD moderada ou grave, quando comparados com altera&#231;&#227;o leve (3,6%) ou di&#225;stole normal (1,1%)<sup>56</sup>.</p>
    <p>Jones e cols.<sup>34</sup> avaliaram a mortalidade em tr&#234;s anos de uma coorte de quase 1.000 pacientes com ICFEN e FE &gt; 0,45, participantes do ensaio cl&#237;nico DIG. Dentre 18 vari&#225;veis analisadas, as que se associaram com morte foram: filtra&#231;&#227;o glomerular, classe funcional de NYHA, sexo masculino, idade avan&#231;ada, &#237;ndice cardiotor&#225;cico, presen&#231;a de DM, necessidade de vasodilatadores ou de diur&#233;ticos. Em fun&#231;&#227;o dessas vari&#225;veis, os pacientes receberam escores de risco e aqueles com os maiores escores (quartil 75) apresentaram mortalidade de 50% no per&#237;odo. Portanto, o paciente com ICFEN precisa ser avaliado por meio de um conjunto amplo de vari&#225;veis cl&#237;nicas e laboratoriais, que extrapolam a defini&#231;&#227;o do grau da disfun&#231;&#227;o ou de outras vari&#225;veis ecocardiogr&#225;ficas.</p>
    <p>
      <bold>Perspectivas</bold>
    </p>
    <p>Finalmente, um aspecto que est&#225; ganhando novamente espa&#231;o na literatura &#233; o questionamento sobre o papel da disfun&#231;&#227;o sist&#243;lica nos quadros de ICFEN. No estudo de Yu e cols., incluindo pacientes normais e pacientes com DD ou IC sist&#243;lica, mostrou-se que o &#237;ndice fun&#231;&#227;o sist&#243;lica avaliado pelo Doppler tissular reduzia progressivamente a medida que piorava o grau de disfun&#231;&#227;o diast&#243;lica<sup>57</sup>. Esse resultado sugere que pacientes com DD tamb&#233;m t&#234;m disfun&#231;&#227;o sist&#243;lica, ainda que sem manifesta&#231;&#227;o cl&#237;nica ou com a FE preservada.</p>
    <p>Outro estudo que utilizou a an&#225;lise da fun&#231;&#227;o ventricular por meio do <italic>strain rate</italic>, identificou associa&#231;&#227;o direta entre pico de contra&#231;&#227;o e pico de relaxamento, em indiv&#237;duos normais ou com diferentes cardiopatias, sugerindo a interdepend&#234;ncia das duas fases do ciclo card&#237;aco<sup>58</sup>.</p>
    <p>Um estudo mais recente, realizado por Yu e cols.<sup>59</sup>, analisou 56 pacientes com ICFEN e evidenciou que v&#225;rios &#237;ndices ecocardiogr&#225;ficos de fun&#231;&#227;o sist&#243;lica, obtidos em repouso, eram significativamente menores quando comparados a 27 indiv&#237;duos saud&#225;veis<sup>59</sup>. Al&#233;m disso, no grupo com ICFEN, esses &#237;ndices n&#227;o aumentavam no exerc&#237;cio. Esse estudo refor&#231;a a hip&#243;tese de que a ICFEN n&#227;o &#233; uma desordem envolvendo, apenas, a di&#225;stole, mesmo que a FE seja preservada. Tamb&#233;m oferece subs&#237;dios para a afirmativa de Lester e cols.<sup>47</sup>: "Talvez, em um futuro pr&#243;ximo, disfun&#231;&#227;o sist&#243;lica e disfun&#231;&#227;o diast&#243;lica n&#227;o ser&#227;o interpretadas clinicamente como termos dicot&#244;micos. Ser&#227;o entendidas, simplesmente, como disfun&#231;&#227;o card&#237;aca."</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Meliza Goi Roscani </p>
        <p> R. Doutor Jos&#233; Augusto de Arruda Botelho, 70 - Jardim Maria Lu </p>
        <p> 17203-030 - Ja&#250;, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="meliza10@cardiol.br">meliza10@cardiol.br</email>, </p>
        <p>
          <email xlink:href="meliza10@hotmail.com">meliza10@hotmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 27/07/09; revisado recebido em 04/09/09; aceito em 21/09/09.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Minist&#233;rio da Sa&#250;de. DATASUS. Informa&#231;&#245;es de sa&#250;de. [Acesso em 2009 fev. 10]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://tabnet.datasus.gov.br">http://tabnet.datasus.gov.br</ext-link></mixed-citation>
        <element-citation publication-type="book">
          <source>DATASUS: Informa&#231;&#245;es de sa&#250;de</source>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Ho KKL, Pinsky    JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study.    J Am Coll Cardiol. 1993; 22 (Suppl A): 6A-13A.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The epidemiology of heart failure: the Framingham study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>6A</fpage>
          <lpage>13A</lpage>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>KKL</given-names>
            </name>
            <name>
              <surname>Pinsky</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Sanderson JE.    Heart failure with a normal ejection fraction. Heart. 2007; 93: 155-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart failure with a normal ejection fraction</article-title>
          <source>Heart</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>155</fpage>
          <lpage>8</lpage>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sanderson</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Zile MR, Brutsaert    DL. New concepts in diastolic dysfunction and diastolic heart failure: Part    II. Circulation. 2002; 105: 1503-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New concepts in diastolic dysfunction and diastolic heart failure: Part II</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1503</fpage>
          <lpage>8</lpage>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zile</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Brutsaert</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Roelandt JRTC.    On-invasive assessment of left ventricular diastolic (dys) function and filling    pressure. Heart Views. 2001; 2 (3): September-November.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>On-invasive assessment of left ventricular diastolic (dys) function and filling pressure</article-title>
          <source>Heart Views</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>September</fpage>
          <lpage>November</lpage>
          <issue>3</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Roelandt</surname>
              <given-names>JRTC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Parmley WW,    Brutsaert DL, Sonnenblick EH. Effects of altered loading on contractile events    in isolated cat papillary muscle. Circ Res. 1969; 24 (4): 521-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of altered loading on contractile events in isolated cat papillary muscle</article-title>
          <source>Circ Res</source>
          <date>
            <year>1969</year>
          </date>
          <fpage>521</fpage>
          <lpage>32</lpage>
          <issue>4</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Parmley</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Brutsaert</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Sonnenblick</surname>
              <given-names>EH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Grossman W,    McLaurin LP, Rolett EL. Alterations in left ventricular relaxation and diastolic    compliance in congestive cardiomyopathy. Cardiovasc Res. 1979; 13 (9): 514-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Alterations in left ventricular relaxation and diastolic compliance in congestive cardiomyopathy</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>1979</year>
          </date>
          <fpage>514</fpage>
          <lpage>22</lpage>
          <issue>9</issue>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grossman</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>McLaurin</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Rolett</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Dodek A, Kassebaum    DG, Bristow JD. Pulmonary edema in coronary-artery disease without cardiomegaly:    paradox of the stiff heart. N Engl J Med. 1972; 286: 1347-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pulmonary edema in coronary-artery disease without cardiomegaly: paradox of the stiff heart</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1972</year>
          </date>
          <fpage>1347</fpage>
          <lpage>50</lpage>
          <volume>286</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dodek</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kassebaum</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Bristow</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Brutsaert DL,    Rademakers FE, Sys SU. Triple control of relaxation: implications in cardiac    disease. Circulation. 1984; 69: 190-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Triple control of relaxation: implications in cardiac disease</article-title>
          <source>Circulation</source>
          <date>
            <year>1984</year>
          </date>
          <fpage>190</fpage>
          <lpage>6</lpage>
          <volume>69</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brutsaert</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Rademakers</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Sys</surname>
              <given-names>SU</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Gaasch WH.    Diagnosis and treatment of heart failure based on left ventricular systolic    or diastolic dysfunction. JAMA. 1994; 27: 1276-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction</article-title>
          <source>JAMA</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>1276</fpage>
          <lpage>80</lpage>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gaasch</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Gaasch WH,    Zile MR. Left ventricular dysfunction and diastolic heart failure. Annu Rev    Med. 2004; 55: 373-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular dysfunction and diastolic heart failure</article-title>
          <source>Annu Rev Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>373</fpage>
          <lpage>94</lpage>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gaasch</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Zile</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Baicu CF, Zile    MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function,    and contractility in patients with diastolic heart failure. Circulation. 2005;    111: 2306-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2306</fpage>
          <lpage>12</lpage>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Baicu</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Zile</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Aurigemma</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Gaasch</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Vasan RS, Larson    MG, Benjamin EJ, Evans JC, Reiss C, Levy D. Congestive heart failure in subjects    with normal versus reduced left ventricular ejection fraction: prevalence and    mortality in a population-based cohort. J Am Coll Cardiol. 1999; 33: 1948-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1948</fpage>
          <lpage>55</lpage>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vasan</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Reiss</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Kirkpatrick    JN, Vannan MA, Narula J, Lang RM. Echocardiography in heart failure. J Am Coll    Cardiol. 2007; 50: 381-96.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiography in heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>381</fpage>
          <lpage>96</lpage>
          <volume>50</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kirkpatrick</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Vannan</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Narula</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Paulus WJ,    Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How    to diagnose diastolic heart failure: a consensus statement on the diagnosis    of heart failure with normal left ventricular ejection fraction by the heart    failure and echocardiography associations of the European Society of Cardiology.    Eur Heart J. 2007; 28: 2539-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European Society of Cardiology</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2539</fpage>
          <lpage>50</lpage>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Paulus</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Tschope</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sanderson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Rusconi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Flachskampf</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Rademakers</surname>
              <given-names>FE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Pfeffer M,    Swedberg K, Granger C, Held P, McMurray J, Michelson E, et al. Effects of candesartan    on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall    programme. Lancet. 2003; 362: 759-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme</article-title>
          <source>Lancet</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>759</fpage>
          <lpage>66</lpage>
          <volume>362</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pfeffer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Swedberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Granger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Held</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Michelson</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Redfield MM,    Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of    systolic and diastolic ventricular dysfunction in the community: appreciating    the scope of the heart failure epidemic. JAMA. 2003; 289: 194-202.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic</article-title>
          <source>JAMA</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>194</fpage>
          <lpage>202</lpage>
          <volume>289</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Redfield</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Burnett</surname>
              <given-names>JC Jr</given-names>
            </name>
            <name>
              <surname>Mahoney</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Rodeheffer</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Owan TE, Hodge    DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and    outcome of heart failure with preserved ejection fraction. N Eng J Med. 2006;    355: 251-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Trends in prevalence and outcome of heart failure with preserved ejection fraction</article-title>
          <source>N Eng J Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>251</fpage>
          <lpage>9</lpage>
          <volume>355</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Owan</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Herges</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Roger</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Redfield</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Lenzen MJ,    Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, et al.    Differences between patients with a preserved and a depressed left ventricular    function: a report from the EuroHeart Failure Survey. Eur Heart J. 2004; 25    (14): 1214-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1214</fpage>
          <lpage>20</lpage>
          <issue>14</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lenzen</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Scholte op Reimer</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Boersma</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vantrimpont</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Follath</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Swedberg</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Peyster E,    Norman J, Domanski M. Prevalence and predictors of heart failure with preserved    systolic function: community hospital admissions of a racially and gender diverse    elderly population. J Card Fail. 2004; 10: 49-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence and predictors of heart failure with preserved systolic function: community hospital admissions of a racially and gender diverse elderly population</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>49</fpage>
          <lpage>54</lpage>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Peyster</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Norman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Domanski</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Aronow WS.    Epidemiology, pathophisiology, prognosis, and treatment of systolic and diastolic    heart failure. Cardiol Rev. 2006; 14 (3): 108-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Epidemiology, pathophisiology, prognosis, and treatment of systolic and diastolic heart failure</article-title>
          <source>Cardiol Rev</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>108</fpage>
          <lpage>24</lpage>
          <issue>3</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Aronow</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Moutinho MA,    Colucci FA, Alcoforado V, Tavares LR, Rachid MB, Rosa ML, et al. Heart failure    with preserved ejection fraction and systolic dysfunction in the community.    Arq Bras Cardiol. 2008; 90: 132-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart failure with preserved ejection fraction and systolic dysfunction in the community</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>132</fpage>
          <lpage>7</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moutinho</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Colucci</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Alcoforado</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tavares</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Rachid</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Kass DA, Bronzwaer    JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure?    Circ Res. 2004; 94 (12): 1533-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>What mechanisms underlie diastolic dysfunction in heart failure?</article-title>
          <source>Circ Res</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1533</fpage>
          <lpage>42</lpage>
          <issue>12</issue>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kass</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Bronzwaer</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Paulus</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Hay I, Rich    J, Ferber P, Burkhoff D, Maurer MS. Role of impaired myocardial relaxation in    the production of elevated left ventricular filling pressure. Am J Physiol Heart    Circ Physiol. 2005; 288: H1203-H1208.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>H1203</fpage>
          <lpage>H1208</lpage>
          <volume>288</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hay</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ferber</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Burkhoff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Burkhoff D,    Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties    via pressure-volume analysis: a guide for clinical, translational, and basic    researchers. Am J Physiol Heart Circ Physiol. 2005; 289: H501-H512.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>H501</fpage>
          <lpage>H512</lpage>
          <volume>289</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Burkhoff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mirsky</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Suga</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. De Stefano    LM, Matsubara LS, Matsubara BB. Myocardial dysfunction with increased ventricular    compliance in volume overload hypertrophy. Eur J Heart Fail. 2006; 8: 784-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial dysfunction with increased ventricular compliance in volume overload hypertrophy</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>784</fpage>
          <lpage>9</lpage>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>De Stefano</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Borbely A,    van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, et al. Cardiomyocyte    stiffness in diastolic heart failure. Circulation. 2005; 111: 774-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiomyocyte stiffness in diastolic heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>774</fpage>
          <lpage>81</lpage>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Borbely</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>van der Velden</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Papp</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Bronzwaer</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Edes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Stienen</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Wehrens XH,    Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase II    phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004; 94:    e61-e70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor</article-title>
          <source>Circ Res</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>e61</fpage>
          <lpage>e70</lpage>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wehrens</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Lehnart</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Reiken</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Matsubara LS,    Matsubara BB, Okoshi MP, Cicogna AC, Janicki JS. Alterations in myocardial collagen    affect rat papillary muscle function. Am J Physiol Heart Cic Physiol. 2000;    279: H1534-H1539.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Alterations in myocardial collagen affect rat papillary muscle function</article-title>
          <source>Am J Physiol Heart Cic Physiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>H1534</fpage>
          <lpage>H1539</lpage>
          <volume>279</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Janicki</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Hein S, Amon    E, Kostin S, Sch&#246;nburg M, El&#228;sser A, Polyakova V, et al. Progression    from compensated hypertrophy to failure in the pressure-overloaded human heart:    structural deterioration and compensatory mechanisms. Circulation. 2003; 107:    984-91.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>984</fpage>
          <lpage>91</lpage>
          <volume>107</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hein</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Amon</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kostin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sch&#246;nburg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>El&#228;sser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Polyakova</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Matsubara LS,    Narikawa S, Ferreira ALA, Paiva SAR, Zornoff LAM, Matsubara BB. Remodela&#231;&#227;o    mioc&#225;rdica na sobrecarga cr&#244;nica de press&#227;o ou de volume    no cora&#231;&#227;o de ratos. Arq Bras Cardiol. 2006; 86: 126-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Remodela&#231;&#227;o mioc&#225;rdica na sobrecarga cr&#244;nica de press&#227;o ou de volume no cora&#231;&#227;o de ratos</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>126</fpage>
          <lpage>30</lpage>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Narikawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>ALA</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>SAR</given-names>
            </name>
            <name>
              <surname>Zornoff</surname>
              <given-names>LAM</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Varela-Roman    A, Grigorian L, Barge E. Heart failure in patients with preserved and deteriorated    left ventricular ejection fraction. Heart. 2005; 91: 489-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart failure in patients with preserved and deteriorated left ventricular ejection fraction</article-title>
          <source>Heart</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>489</fpage>
          <lpage>94</lpage>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Varela-Roman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grigorian</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Barge</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Yancy CW, Lopatin    M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management and    in-hospital outcomes of patients admitted with acute decompensated heart failure    with preserved systolic function. A report from the Acute Decompensated Heart    Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006; 47: 76-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical presentation, management and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>76</fpage>
          <lpage>84</lpage>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yancy</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Lopatin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>De Marco</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fonarow</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Jones RC, Francis    GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved    systolic function in the Digitalis Investigation Group Trial. J Am Coll Cardiol.    2004; 44: 1025-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group Trial</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1025</fpage>
          <lpage>9</lpage>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Lauer</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Bhatia RS,    Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure    with preserved ejection fraction in a population-based study. N Engl J Med.    2006; 355: 260-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Outcome of heart failure with preserved ejection fraction in a population-based study</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>260</fpage>
          <lpage>9</lpage>
          <volume>355</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bhatia</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Tu</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Austin</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haouzi</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Yamamoto K,    Masuyama T, Doi Y, Naito J, Mano T, Kondo H, et al. Noninvasive assessment of    LV relaxation using continuous wave Doppler aortic regurgitant velocity curve:    its comparative value to the mitral regurgitation method. Circulation. 1995;    91: 192-200.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Noninvasive assessment of LV relaxation using continuous wave Doppler aortic regurgitant velocity curve: its comparative value to the mitral regurgitation method</article-title>
          <source>Circulation</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>192</fpage>
          <lpage>200</lpage>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Masuyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Doi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Naito</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Honda Y, Yokota    Y, Yokoyama M. Evaluation of left ventricular relaxation using the continuous-wave    Doppler velocity profile of aortic regurgitation: noninvasive measurement of    left ventricular negative dP/dt and time constant. Clin Cardiol. 1996; 19: 709-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation of left ventricular relaxation using the continuous-wave Doppler velocity profile of aortic regurgitation: noninvasive measurement of left ventricular negative dP/dt and time constant</article-title>
          <source>Clin Cardiol</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>709</fpage>
          <lpage>15</lpage>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Honda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yokota</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Sociedade Brasileira    de Cardiologia. III Diretriz brasileira de insufici&#234;ncia card&#237;aca    cr&#244;nica. Arq Bras Cardiol. 2009; 93: 1-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1</fpage>
          <lpage>71</lpage>
          <volume>93</volume>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Nagueh SF,    Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations    for the evaluation of left ventricular diastolic function by echocardiography.    J Am Soc Echocardiogr. 2009; 22 (2): 107-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recommendations for the evaluation of left ventricular diastolic function by echocardiography</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>107</fpage>
          <lpage>33</lpage>
          <issue>2</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nagueh</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Appleton</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Gillebert</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Smiseth</surname>
              <given-names>OA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Mesquita ET,    Jorge AJL. Insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o    normal - novos crit&#233;rios diagn&#243;sticos e avan&#231;os fisiopatol&#243;gicos.    Arq Bras Cardiol. 2009; 93 (2): 180-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o normal - novos crit&#233;rios diagn&#243;sticos e avan&#231;os fisiopatol&#243;gicos</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>180</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Jorge</surname>
              <given-names>AJL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Little WC,    Oh JK. Echocardiographic evaluation of diastolic function can be used to guide    clinical care. Circulation. 2009; 120 (9): 802-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiographic evaluation of diastolic function can be used to guide clinical care</article-title>
          <source>Circulation</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>802</fpage>
          <lpage>9</lpage>
          <issue>9</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Little</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Tsh&#246;pe    C, Paulus. Is echocardiographic evaluation of diastolic function useful in determining    clinical care? Doppler echocardiography yields bubious estimates of left ventricular    diastolic pressures. Circulation. 2009; 120 (9): 810-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Is echocardiographic evaluation of diastolic function useful in determining clinical care?: Doppler echocardiography yields bubious estimates of left ventricular diastolic pressures</article-title>
          <source>Circulation</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>810</fpage>
          <lpage>20</lpage>
          <issue>9</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tsh&#246;pe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Paulus</surname>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. Vasan RS, Levy    D. Defining diastolic heart failure: a call for standardized diastolic criteria.    Circulation. 2000; 101: 2118-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Defining diastolic heart failure: a call for standardized diastolic criteria</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>2118</fpage>
          <lpage>21</lpage>
          <volume>101</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vasan</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B44">
        <mixed-citation>44. Zile MR, Gaasch    WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, et al. Heart failure with    a normal ejection fraction: is measurement of diastolic function necessary to    make the diagnosis of diastolic heart failure? Circulation. 2001; 104: 779-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?</article-title>
          <source>Circulation</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>779</fpage>
          <lpage>82</lpage>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zile</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Gaasch</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Carroll</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Aurigemma</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Schaer</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B45">
        <mixed-citation>45. Yturralde FR,    Gaasch WH. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc    Dis. 2005; 47: 314-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diagnostic criteria for diastolic heart failure</article-title>
          <source>Prog Cardiovasc Dis</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>314</fpage>
          <lpage>9</lpage>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yturralde</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Gaasch</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B46">
        <mixed-citation>46. Pritchett AM,    Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield M. Diastolic dysfunction    and left atrial volume. J Am Coll Cardiol. 2005; 45: 87-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diastolic dysfunction and left atrial volume</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>87</fpage>
          <lpage>92</lpage>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pritchett</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Mahoney</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Rodeheffer</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Karon</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Redfield</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B47">
        <mixed-citation>47. Lester SJ,    Tajik J, Nishimura RA, Oh JK, Khandheria BK, Seward JB. Unlocking the mysteries    of diastolic function. J Am Coll Cardiol. 2008; 51: 679-89.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Unlocking the mysteries of diastolic function</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>679</fpage>
          <lpage>89</lpage>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lester</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Tajik</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Khandheria</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Seward</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B48">
        <mixed-citation>48. Clerico A,    Iervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, et al. Circulating    levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive    and specific immunoradiometric assays in normal subjects and in patients with    different degrees of heart failure. J Endocrinol Invest. 1998; 21 (3): 170-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure</article-title>
          <source>J Endocrinol Invest</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>170</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Clerico</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Iervasi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Del Chicca</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Emdin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maffei</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nannipieri</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B49">
        <mixed-citation>49. Omland T, Aakvaag    A, Bonarjee VVS, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic    peptide as an indicator of left ventricular systolic function and long-term    survival after acute myocardial infarction: comparison with plasma atrial natriuretic    peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996; 93    (11): 1963-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide</article-title>
          <source>Circulation</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1963</fpage>
          <lpage>9</lpage>
          <issue>11</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Omland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aakvaag</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bonarjee</surname>
              <given-names>VVS</given-names>
            </name>
            <name>
              <surname>Caidahl</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lie</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Nilsen</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B50">
        <mixed-citation>50. Krishnaswamy    P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, et al Utility of B-natriuretic    peptide levels in identifying patients with left ventricular systolic or diastolic    dysfunction. Am J Med. 2001; 111: 274-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction</article-title>
          <source>Am J Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>274</fpage>
          <lpage>9</lpage>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Krishnaswamy</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lubien</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Clopton</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Koon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kazanegra</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wanner</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B51">
        <mixed-citation>51. Yusuf S, Pfeffer    MA, Swedberg K, Granger CB, Held P, McMurray J, et al. Effects of candesartan    in patients with chronic heart failure and preserved left-ventricular ejection    fraction: the CHARM-Preserved Trial. Lancet. 2003; 362: 777-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial</article-title>
          <source>Lancet</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>777</fpage>
          <lpage>81</lpage>
          <volume>362</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Swedberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Granger</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Held</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B52">
        <mixed-citation>52. Cleland JG,    Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in    elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;    27: 2238-45.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The perindopril in elderly people with chronic heart failure (PEP-CHF) study</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>2238</fpage>
          <lpage>45</lpage>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cleland</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Tendera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Adamus</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Freemantle</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Polonski</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B53">
        <mixed-citation>53. Shibata MC,    Flather MD, B&#246;hm M, Borbola J, Cohen-Solal A, Dumitrascu D, et al. Study    of the effects of nebivolol intervention on outcomes and rehospitalisation in    seniors with Heart Failure (SENIORS). Rationale and design. Int J Cardiol. 2002;    86: 77-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Study of the effects of nebivolol intervention on outcomes and rehospitalisation in seniors with Heart Failure (SENIORS): Rationale and design</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>77</fpage>
          <lpage>85</lpage>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shibata</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Flather</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>B&#246;hm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Borbola</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cohen-Solal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dumitrascu</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B54">
        <mixed-citation>54. Ahmed A, Rich    MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects on digoxin on morbitity    and mortality in diastolic heart failure: the ancillary digitalis investigation    group trial. Circulation. 2006; 114: 397-403.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects on digoxin on morbitity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial</article-title>
          <source>Circulation</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>397</fpage>
          <lpage>403</lpage>
          <volume>114</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ahmed</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Fleg</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Zile</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Kitzman</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B55">
        <mixed-citation>55. Massie BM,    Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR. Irbesartan in patients    with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359:    1-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Irbesartan in patients with heart failure and preserved ejection fraction</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1</fpage>
          <lpage>12</lpage>
          <volume>359</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Massie</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Carson</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Komajda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McKelvie</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zile</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B56">
        <mixed-citation>56. Ren X, Ristow    B, Na B, Ali S, Schiller NB, Whooley MA. Prevalence and prognosis of asymptomatic    left ventricular diastolic dysfunction ambulatory patients with coronary heart    disease. Am J Cardiol. 2007; 99: 1643-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction ambulatory patients with coronary heart disease</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1643</fpage>
          <lpage>7</lpage>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ren</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ristow</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Na</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Whooley</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B57">
        <mixed-citation>57. Yu CM, Lin    H, Yang H, Kong SL, Zhang Q, Lee SWL. Progression of systolic abnormalities    in patients with "isolated" diastolic heart failures and diastolic dysfunction.    Circulation. 2002; 105: 1195-201.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Progression of systolic abnormalities in patients with "isolated" diastolic heart failures and diastolic dysfunction</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1195</fpage>
          <lpage>201</lpage>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SWL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B58">
        <mixed-citation>58. Takamura T,    Dohi K, Fujimoto N, Kurita T, Kato S. Coupling of left ventricular relaxation    to systolic contraction in normal, hypertrophied and dilated myocardium quantified    by speckel-tracking global strain and strain rate imaging. Circulation. 2007;    116: 708-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Coupling of left ventricular relaxation to systolic contraction in normal, hypertrophied and dilated myocardium quantified by speckel-tracking global strain and strain rate imaging</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>708</fpage>
          <lpage>9</lpage>
          <volume>116</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Takamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dohi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kurita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B59">
        <mixed-citation>59. Yu TT, Wenzelburger    F, Lee E, Heatlie G, Leyva F, Patel K, et al. The pathophysiology of heart failure    with normal ejection fraction. J Am Coll Cardiol. 2009; 54: 36-46.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The pathophysiology of heart failure with normal ejection fraction</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>36</fpage>
          <lpage>46</lpage>
          <volume>54</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Wenzelburger</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Heatlie</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Leyva</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Insuficiencia card&#237;aca con fracci&#243;n de eyecci&#243;n normal</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>La insuficiencia card&#237;aca con fracci&#243;n de eyecci&#243;n normal (ICFEN) es un s&#237;ndrome complejo que viene siendo ampliamente estudiado desde la &#250;ltima d&#233;cada. Es causado por disfunci&#243;n ventricular diast&#243;lica manifestada por m&#233;todos complementarios como estudio hemodin&#225;mico o ecocardiograma, en presencia de fracci&#243;n de eyecci&#243;n preservada. Afecta preferentemente a individuos m&#225;s a&#241;osos y con comorbilidades, como hipertensi&#243;n arterial sist&#233;mica, insuficiencia coronaria y obesidad. Los mecanismos fisiopatol&#243;gicos son complejos y multifactoriales, involucrando la rigidez pasiva del miocardio, la geometr&#237;a ventricular, la fuerza de contenci&#243;n peric&#225;rdica y la interacci&#243;n entre los ventr&#237;culos. Los objetivos principales del tratamiento son reducir la congesti&#243;n venosa pulmonar, la frecuencia card&#237;aca y controlar las comorbilidades. Todav&#237;a no hay evidencias de que el uso de medicaciones espec&#237;ficas, como inhibidores de la enzima de conversi&#243;n o betabloqueadores, interfieran en la mortalidad. Los factores de peor pron&#243;stico incluyen la edad avanzada, presencia de disfunci&#243;n renal, diabetes, clase funcional III y IV (NYHA) y estado avanzado de disfunci&#243;n diast&#243;lica, con patr&#243;n restrictivo al llenado ventricular. Otro aspecto viene cobrando espacio en la bibliograf&#237;a es el cuestionamiento del papel de la disfunci&#243;n sist&#243;lica en los cuadros de ICFEN. Todos estos aspectos se abordan detalladamente en la presente revisi&#243;n.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia card&#237;aca</kwd>
        <kwd>di&#225;stole</kwd>
        <kwd>cardiomegalia</kwd>
        <kwd>ecocardiograf&#237;a</kwd>
        <kwd>distensi&#243;n</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO DE REVISI&#211;N</bold>
      </p>
      <p>
        <bold>Insuficiencia card&#237;aca con fracci&#243;n de eyecci&#243;n normal</bold>
      </p>
      <p>
        <bold>Meliza Goi Roscani; Luiz Shiguero Matsubara; Beatriz Bojikian Matsubara</bold>
      </p>
      <p>Faculdade de Medicina de Botucatu - UNESP, S&#227;o Paulo, SP - Brasil</p>
      <p>
        <xref ref-type="corresp" rid="end-body2">Correspondencia</xref>
      </p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>La insuficiencia card&#237;aca con fracci&#243;n de eyecci&#243;n normal (ICFEN) es un s&#237;ndrome complejo que viene siendo ampliamente estudiado desde la &#250;ltima d&#233;cada. Es causado por disfunci&#243;n ventricular diast&#243;lica manifestada por m&#233;todos complementarios como estudio hemodin&#225;mico o ecocardiograma, en presencia de fracci&#243;n de eyecci&#243;n preservada. Afecta preferentemente a individuos m&#225;s a&#241;osos y con comorbilidades, como hipertensi&#243;n arterial sist&#233;mica, insuficiencia coronaria y obesidad. Los mecanismos fisiopatol&#243;gicos son complejos y multifactoriales, involucrando la rigidez pasiva del miocardio, la geometr&#237;a ventricular, la fuerza de contenci&#243;n peric&#225;rdica y la interacci&#243;n entre los ventr&#237;culos. Los objetivos principales del tratamiento son reducir la congesti&#243;n venosa pulmonar, la frecuencia card&#237;aca y controlar las comorbilidades. Todav&#237;a no hay evidencias de que el uso de medicaciones espec&#237;ficas, como inhibidores de la enzima de conversi&#243;n o betabloqueadores, interfieran en la mortalidad. Los factores de peor pron&#243;stico incluyen la edad avanzada, presencia de disfunci&#243;n renal, diabetes, clase funcional III y IV (NYHA) y estado avanzado de disfunci&#243;n diast&#243;lica, con patr&#243;n restrictivo al llenado ventricular. Otro aspecto viene cobrando espacio en la bibliograf&#237;a es el cuestionamiento del papel de la disfunci&#243;n sist&#243;lica en los cuadros de ICFEN. Todos estos aspectos se abordan detalladamente en la presente revisi&#243;n.</p>
      <p><bold>Palabras clave:</bold> Insuficiencia card&#237;aca, di&#225;stole, cardiomegalia, ecocardiograf&#237;a, distensi&#243;n.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia card&#237;aca (IC) es un s&#237;ndrome complejo caracterizado por intolerancia a los esfuerzos f&#237;sicos, retenci&#243;n de l&#237;quidos y fen&#243;menos congestivos, y despu&#233;s del inicio de los s&#237;ntomas, presenta altas tasas de morbilidad-mortalidad. Se trata de una condici&#243;n con prevalencia creciente en el mundo y se estima que, en 2025, habr&#225; cinco millones de casos en Brasil<sup>1</sup>. El riesgo acumulado de desarrollar IC en el transcurso de una d&#233;cada es mayor en la poblaci&#243;n de adultos mayores que en j&#243;venes<sup>2</sup>. Por lo tanto, en los adultos mayores con se&#241;ales o s&#237;ntomas cl&#225;sicos de IC, la intolerancia a los esfuerzos f&#237;sicos se debe frecuentemente al aumento de la presi&#243;n en el atrio izquierdo, aun cuando la fracci&#243;n de eyecci&#243;n permanezca dentro de los l&#237;mites de la normalidad. Esta condici&#243;n corresponde a la insuficiencia card&#237;aca diast&#243;lica (ICD). La entidad viene siendo foco de discusi&#243;n en la &#250;ltima d&#233;cada y varios conceptos han sido reformulados, justificando la presente revisi&#243;n.</p>
      <p>
        <bold>Terminolog&#237;a</bold>
      </p>
      <p>Existe una controversia en la bibliograf&#237;a sobre cu&#225;l es la denominaci&#243;n m&#225;s apropiada para es condici&#243;n cl&#237;nica "IC diast&#243;lica" o "IC con funci&#243;n sist&#243;lica preservada". Aquellos que defienden la denominaci&#243;n de IC con funci&#243;n sist&#243;lica preservada dicen que esta forma m&#225;s descriptiva evita confusi&#243;n o diagn&#243;stico incorrecto, teniendo en vista que la disfunci&#243;n diast&#243;lica est&#225; presente en casi todos los casos de IC<sup>3</sup>.</p>
      <p>Los autores que defienden la denominaci&#243;n de IC diast&#243;lica dicen que al especificar el t&#233;rmino "diast&#243;lica", ya se sobreentiende que est&#225; siendo excluida la disfunci&#243;n sist&#243;lica significativa y el fen&#243;meno congestivo depende de la disfunci&#243;n diast&#243;lica (DD). Tambi&#233;n se hace referencia a que el t&#233;rmino insuficiencia card&#237;aca con funci&#243;n sist&#243;lica preservada no permite la distinci&#243;n de los casos de valvulopat&#237;a mitral en la que la fracci&#243;n de eyecci&#243;n (FE) es normal y la IC no se debe a la disfunci&#243;n diast&#243;lica<sup>4</sup><sub>.</sub></p>
      <p>Actualmente, varios autores sustituyeron el t&#233;rmino funci&#243;n sist&#243;lica preservada por FE normal, entendiendo que pacientes con IC diast&#243;lica pueden presentar alg&#250;n grado de disfunci&#243;n sist&#243;lica. En la bibliograf&#237;a, estas denominaciones de utilizan como sin&#243;nimas. En esta revisi&#243;n se utilizar&#225;n preferentemente el t&#233;rmino IC con FE normal, o ICFEN, por ser m&#225;s descriptivo.</p>
      <p>
        <bold>Aspectos hist&#243;ricos y conceptos</bold>
      </p>
      <p>Seg&#250;n Roelandt, la primera asociaci&#243;n entre relajaci&#243;n mioc&#225;rdica y funci&#243;n ventricular fue descrita en 1923, por Yendell Handerson, el cual afirm&#243; que la relajaci&#243;n mioc&#225;rdica era tan importante como la contracci&#243;n<sup>5</sup>. Dio el ejemplo de que un paciente a&#241;oso, con relajaci&#243;n mioc&#225;rdica retardada, podr&#237;a presentar intolerancia a los esfuerzos f&#237;sicos, Por lo tanto, se describ&#237;a lo que vendr&#237;a a constituir la insuficiencia card&#237;aca con FE normal (ICFEN).</p>
      <p>No obstante, el concepto s&#243;lo recibi&#243; atenci&#243;n en los a&#241;os 60<sup>6</sup> y en la d&#233;cada siguiente, con estudios asociando a isquemia mioc&#225;rdica con disfunci&#243;n diast&#243;lica del ventr&#237;culo izquierdo (VI)<sup>7,8</sup>.</p>
      <p>En 1984, Brutsaert describi&#243; su teor&#237;a sobre el triple control de la relajaci&#243;n mioc&#225;rdica<sup>9</sup>, la cual depender&#237;a de la precarga, de la desactivaci&#243;n muscular y de la uniformidad de desactivaci&#243;n en el tiempo y en el espacio.</p>
      <p>Gaasch defini&#243; el t&#233;rmino disfunci&#243;n diast&#243;lica en 1994, como "incapacidad del coraz&#243;n de acomodar el volumen de sangre durante la di&#225;stole con bajas presiones; el llenado ventricular es retardado o incompleto y la presi&#243;n atrial aumenta, causando congesti&#243;n pulmonar o sist&#233;mica"<sup>10</sup>. Diez a&#241;os m&#225;s tarde, en 2004, el mismo autor<sup>11</sup> redefini&#243; la entidad, escribiendo: "La disfunci&#243;n diast&#243;lica puede ocurrir independientemente de la FE ser normal o reducida. Si el paciente con FE normal desarrolla intolerancia al esfuerzo, disnea y congesti&#243;n, es necesario usar el t&#233;rmino Insuficiencia Card&#237;aca Diast&#243;lica."</p>
      <p>Recientemente, varios investigadores argumentaron que la ICD ser&#237;a, de hecho, la manifestaci&#243;n cl&#237;nica de disfunci&#243;n sist&#243;lica transitoria, secundaria a la isquemia o hipertensi&#243;n. Para refutar este argumento, Baicu y colaboradores evaluaron pacientes con diagn&#243;stico de ICD e individuos sin disfunci&#243;n ventricular por medio de manometr&#237;a del VI asociado al c&#225;lculo del volumen ventricular<sup>12</sup>. Los pacientes con ICD presentaron todos los &#237;ndices de funci&#243;n sist&#243;lica global y de contractilidad mioc&#225;rdica preservados. Los autores concluyeron que, aun en presencia de discretas alteraciones de la funci&#243;n sist&#243;lica, el t&#233;rmino ICD es aplicable, teniendo en vista la evidente contribuci&#243;n de la disfunci&#243;n diast&#243;lica en el cuadro de IC.</p>
      <p>
        <bold>Epidemiolog&#237;a</bold>
      </p>
      <p>Entre los pacientes con el s&#237;ndrome cl&#237;nico de IC, la prevalencia de ICFEN var&#237;a ampliamente en los diferentes estudios, de 40%-71%, con promedio de 56%<sup>13</sup>. Esta variaci&#243;n se debe, probablemente, a la definici&#243;n adoptada para el t&#233;rmino "funci&#243;n sist&#243;lica preservada" y a las caracter&#237;sticas de la poblaci&#243;n estudiada, como edad, raza y prevalencia del sexo femenino. Por ejemplo, dos estudios publicados en 2000, uno desarrollado en la poblaci&#243;n americana y otro en la poblaci&#243;n europea, utilizaron tres categor&#237;as de funci&#243;n sist&#243;lica: preservada, discretamente reducida y moderada o gravemente reducida. Con todo, en el estudio americano la funci&#243;n sist&#243;lica fue considerada preservada si FE = 0,50 y correspondi&#243; al 24% de los pacientes<sup>14</sup>; en el estudio europeo la FE = 0,45 fue considerada preservada y correspondi&#243; al 38% de los pacientes<sup>15</sup>. Otro aspecto es el hecho de algunos estudios agrupar pacientes con FE normal o discretamente reducida<sup>16</sup>.</p>
      <p>Con relaci&#243;n a la edad, se sabe que la prevalencia de la ICFEN est&#225; directamente asociada a esta variable<sup>4</sup>. De esos individuos, el 41% presentaba FE mayor que 0,50<sup>17</sup>. Resultados similares fueron encontrados en publicaciones posteriores<sup>18-20</sup>. En poblaciones de adultos mayores con m&#225;s de 70 a&#241;os, la prevalencia puede superar el 50%<sup>21</sup>. Finalmente, casu&#237;sticas de pacientes con IC y con predominio del sexo femenino pueden presentar &#237;ndices de FE preservadas con frecuencias tan elevadas como el 60%<sup>22</sup>.</p>
      <p>
        <bold>Fisiopatolog&#237;a</bold>
      </p>
      <p>El llenado ventricular en la di&#225;stole se define por las caracter&#237;sticas f&#237;sicas de la c&#225;mara, que establecen las relaciones entre presi&#243;n y volumen. Estas caracter&#237;sticas f&#237;sicas est&#225;n regidas por la complacencia ventricular que describe el cociente entre una variaci&#243;n dada de volumen y su correspondiente variaci&#243;n de presi&#243;n<sup>23-27</sup>. Aunque estos conceptos sean aplicables a los dos ventr&#237;culos, se utilizar&#225; el ventr&#237;culo izquierdo como referencia para facilitar la comprensi&#243;n.</p>
      <p>La complacencia debe ser analizada considerando un ventr&#237;culo dado, al final del llenado diast&#243;lico, despu&#233;s de la contracci&#243;n atrial, cuando todos los fen&#243;menos activos de la di&#225;stole, te&#243;ricamente, ya se completaron (<xref ref-type="fig" rid="f1-body2">Figura 1</xref>). En ese momento particular del ciclo card&#237;aco, si el ventr&#237;culo opera en diferentes condiciones de carga, los puntos de asociaci&#243;n presi&#243;n-volumen describen una curva caracter&#237;stica en el plano cartesiano, t&#237;pica de una funci&#243;n exponencial.</p>
      <fig id="f1-body2">
        <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf01-es.jpg"/></fig>
      <p>La primera implicaci&#243;n cl&#237;nica de esa caracter&#237;stica es que en un ventr&#237;culo dado, conteniendo poco volumen, aumentos adicionales expresivos de volumen son tolerados sin variaci&#243;n de la presi&#243;n. Con todo, despu&#233;s de un cierto l&#237;mite, peque&#241;os aumentos de volumen causan variaciones importantes en la presi&#243;n diast&#243;lica. Es decir, un mismo ventr&#237;culo puede presentar complacencia variable, dependiendo del volumen en que opera<sup>25</sup>.</p>
      <p>La segunda implicaci&#243;n es que ventr&#237;culos peque&#241;os soportan vol&#250;menes menores, mientras que ventr&#237;culos grandes pueden contener vol&#250;menes mayores con baja presi&#243;n. La <xref ref-type="fig" rid="f2-body2">Figura 2</xref> ilustra de forma esquem&#225;tica las desviaciones de la curva de complacencia en las situaciones patol&#243;gicas. En la hipertrofia conc&#233;ntrica, por ejemplo, ocurren variaciones m&#225;s acentuadas de la presi&#243;n para una variaci&#243;n de volumen dada, aun dentro de los l&#237;mites considerados normales. En esos casos, el paciente est&#225; propenso a desarrollar congesti&#243;n venosa, aun cuando la FE est&#233; preservada. Al contrario, en las c&#225;maras dilatadas, cuando la curva est&#225; desviada hacia la derecha, la presi&#243;n diast&#243;lica alcanzar&#225; valores elevados, s&#243;lo cuando haya exceso de volumen. Es lo que sucede en las disfunciones sist&#243;licas, cuando el volumen residual en la cavidad est&#225; aumentado<sup>23,25</sup>.</p>
      <fig id="f2-body2">
        <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf02-es.jpg"/></fig>
      <p>La di&#225;stole comprende cuatro fases: relajaci&#243;n isovolum&#233;trica, llenado ventricular r&#225;pido, di&#225;stasis y contracci&#243;n atrial. Durante la relajaci&#243;n isovolum&#233;trica, no hay llenado ventricular. La fase de llenado r&#225;pida va del 70% al 80% del llenado ventricular total, en individuos normales y depende directamente del gradiente de presi&#243;n atrioventricular. La di&#225;stasis es la fase en que las presiones de atrio y del ventr&#237;culo son pr&#225;cticamente iguales y el flujo transvalvular mitral corresponde a apenas el 5% del flujo total. La di&#225;stasis podr&#237;a ser entendida como la reserva funcional que garantiza el llenado ventricular, a pesar de variaciones de la frecuencia card&#237;aca. Es decir, habiendo taquicardia, el per&#237;odo a ser consumido ser&#237;a la di&#225;stasis, As&#237;, dentro de ciertos l&#237;mites, el llenado no ser&#237;a perjudicado. La contracci&#243;n atrial contribuye con el 15% al 25% del volumen diast&#243;lico, y en situaciones fisiol&#243;gicas, cursa con mantenimiento de la presi&#243;n atrial media.</p>
      <p>En los l&#237;mites fisiol&#243;gicos de variaci&#243;n de la frecuencia card&#237;aca, y considerando esas cuatro fases de la di&#225;stole, los factores que afectan la complacencia ventricular y est&#225;n asociados a ICFEN son: rigidez pasiva del miocardio, geometr&#237;a ventricular, fuerza de contenci&#243;n peric&#225;rdica e interacci&#243;n entre os ventr&#237;culos.</p>
      <p>
        <bold>Rigidez pasiva mioc&#225;rdica</bold>
      </p>
      <p>La rigidez pasiva del miocardio tambi&#233;n corresponde a una propiedad mec&#225;nica y describe la fuerza necesaria a ser aplicada al m&#250;sculo, para producir una deformaci&#243;n dada. Por lo tanto, seg&#250;n este concepto f&#237;sico, el miocardio se considera un material inerte, con caracter&#237;sticas f&#237;sicas que dependen intr&#237;nsecamente de su composici&#243;n y no del proceso activo de la relajaci&#243;n<sup>27</sup>.</p>
      <p>Con todo, biol&#243;gicamente, la relajaci&#243;n alterada puede aumenta la rigidez pasiva del miocardio, en la medida en que no se completa. Es decir, al final de la di&#225;stole, el m&#250;sculo todav&#237;a parcialmente contra&#237;do, se comporta como un material m&#225;s r&#237;gido. Otro aspecto relevante es el caso de relajaci&#243;n mioc&#225;rdica apenas retardada. Te&#243;ricamente, esta alteraci&#243;n no deber&#237;a perjudicar la complacencia ventricular, ni causar IC. Sin embargo, habiendo taquicardia y supresi&#243;n de la di&#225;stasis, la relajaci&#243;n m&#225;s lenta puede comportarse como una relajaci&#243;n incompleta, y el llenado ventricular suceder&#225; con presi&#243;n elevada, pudiendo causar fen&#243;menos congestivos. Esta es una de las explicaciones de por qu&#233; pacientes con ICFEN no toleran elevaciones de la frecuencia card&#237;aca.</p>
      <p>De modo simplificado, se puede afirmar que la rigidez pasiva mioc&#225;rdica depende de la relajaci&#243;n y de la composici&#243;n del m&#250;sculo.</p>
      <p>
        <bold>Relajaci&#243;n mioc&#225;rdica</bold>
      </p>
      <p>La relajaci&#243;n mioc&#225;rdica exige gasto energ&#233;tico y tiene su inicio durante la fase final de la eyecci&#243;n sist&#243;lica. Este proceso influye principalmente las fases iniciales de la di&#225;stole. En corazones normales, aun durante el ejercicio f&#237;sico, el proceso se completa en este per&#237;odo. La liberaci&#243;n de catecolaminas acelera la relajaci&#243;n de las fibras mioc&#225;rdicas, manteniendo la baja presi&#243;n diast&#243;lica, a pesar de la taquicardia y del aumento del retorno venoso. Es la relajaci&#243;n mioc&#225;rdica la que genera el gradiente de presi&#243;n entre el atrio izquierdo (AI) y el VI, sin elevaci&#243;n adicional de la presi&#243;n atrial izquierda, previniendo la congesti&#243;n pulmonar<sup>24</sup>.</p>
      <p>La relajaci&#243;n depende principalmente de la oferta de ATP y de la homeostasis del calcio intracelular. La funci&#243;n inadecuada de varias prote&#237;nas involucradas en la homeostasis del calcio tambi&#233;n puede afectar profundamente el proceso de relajaci&#243;n<sup>28</sup>.</p>
      <p>En los casos de atraso en la relajaci&#243;n del VI en los cuales todav&#237;a hay mantenimiento de la presi&#243;n atrial izquierda, ocurre la disminuci&#243;n del gradiente de presi&#243;n atrioventricular y la prolongaci&#243;n del tiempo de llenado r&#225;pido. Como consecuencia, hay una reducci&#243;n del llenado ventricular en la fase inicial de la di&#225;stole. En etapas m&#225;s avanzadas, cuando adem&#225;s de las alteraciones de la relajaci&#243;n mioc&#225;rdica hay reducci&#243;n de la complacencia ventricular, las presiones en las dos c&#225;maras, atrio y ventr&#237;culo, crecen y los pacientes pueden presentar alg&#250;n grado de intolerancia a los esfuerzos. Alteraciones m&#225;s graves, como la relajaci&#243;n incompleta y complacencia reducida, llevan al aumento de la presi&#243;n diast&#243;lica, hasta el punto de restringir el vaciado atrial. En esta condici&#243;n, en general, hay se&#241;ales t&#237;picas de IC izquierda, como disnea a peque&#241;os esfuerzos o en reposo.</p>
      <p>
        <bold>Composici&#243;n del miocardio</bold>
      </p>
      <p>Los miocitos ocupan el 70% del volumen del m&#250;sculo card&#237;aco. Adem&#225;s de ellos, existen los vasos, los fibroblastos y una red fibrilar de col&#225;geno, de estructura bastante compleja. Aunque el col&#225;geno ocupe s&#243;lo el 4%-6% del volumen del m&#250;sculo, su alta rigidez pasiva, similar a la del acero, hace que peque&#241;as variaciones en su concentraci&#243;n produzcan efectos expresivos en la rigidez pasiva del miocardio<sup>29</sup>.</p>
      <p>En las agresiones card&#237;acas, los factores mec&#225;nicos conducen a la activaci&#243;n secundaria de factores bioqu&#237;micos (activaci&#243;n neurohormonal y liberaci&#243;n de citocinas proinflamatorias). Entre los varios efectos de estas modificaciones est&#225;n la p&#233;rdida de miocitos, la producci&#243;n de inhibidores de las metaloproteasas tisulares por el endotelio y la producci&#243;n de col&#225;geno y colagenasas por los fibroblastos. La interacci&#243;n de esos factores determina la concentraci&#243;n de col&#225;geno en el proceso de remodelado mioc&#225;rdico.</p>
      <p>Trat&#225;ndose de composici&#243;n del miocardio, no es s&#243;lo la alteraci&#243;n del col&#225;geno la que promueve la disfunci&#243;n diast&#243;lica. La hipertrofia mioc&#225;rdica es otra variable importante, que marca la evoluci&#243;n de la agresi&#243;n card&#237;aca inicial a la insuficiencia card&#237;aca y muerte cardiovascular (CV). En los casos de hipertrofia conc&#233;ntrica, hay reducci&#243;n de la reserva coronaria y aumento del riesgo de isquemia mioc&#225;rdica, independientemente de la presencia de enfermedad ateroscler&#243;tica coronaria, causando los disturbios de relajaci&#243;n ya discutidos. El propio cambio de la geometr&#237;a del ventr&#237;culo podr&#225; constituir un factor independiente de alteraci&#243;n de la complacencia y disfunci&#243;n diast&#243;lica<sup>30</sup>.</p>
      <p>
        <bold>Geometr&#237;a del ventr&#237;culo</bold>
      </p>
      <p>La hipertrofia exc&#233;ntrica (multiplicaci&#243;n en serie de los sarc&#243;meros) resulta en la dilataci&#243;n de la c&#225;mara ventricular proporcionando mayor tolerancia al volumen que llega a los ventr&#237;culos. En este caso, los fen&#243;menos congestivos s&#243;lo aparecen cuando el volumen dentro de la c&#225;mara excede determinado l&#237;mite. Es decir, la congesti&#243;n y la disfunci&#243;n diast&#243;lica son secundarias a la disfunci&#243;n sist&#243;lica. Es importante comprender que el ventr&#237;culo dilatado puede comportarse como c&#225;mara complaciente, aun cuando el miocardio presente concentraci&#243;n anormal de fibrosis y rigidez pasiva aumentada.</p>
      <p>La c&#225;mara con geometr&#237;a conc&#233;ntrica tiene comportamiento diferente porque el ventr&#237;culo es m&#225;s propenso a la disfunci&#243;n diast&#243;lica, independientemente de la presencia o de la ausencia de hipertrofia ventricular izquierda (HVI). Desde el punto de vista f&#237;sico, es f&#225;cil entender que una c&#225;mara de radio peque&#241;o y con paredes gruesas presente mayor resistencia al estiramiento. No obstante, el cambio de geometr&#237;a es m&#225;s complejo y extrapola la caracter&#237;stica f&#237;sica. La geometr&#237;a conc&#233;ntrica est&#225; asociada a cambios metab&#243;licos expresivos, activaci&#243;n funcional y cambio del perfil de expresi&#243;n g&#233;nica del m&#250;sculo<sup>31</sup>. Todos estos factores act&#250;an sin&#233;rgicamente en el sentido de fomentar la disfunci&#243;n mioc&#225;rdica.</p>
      <p>
        <bold>Fuerza de contenci&#243;n peric&#225;rdica</bold>
      </p>
      <p>El coraz&#243;n est&#225; contenido dentro de una estructura r&#237;gida compuesta por col&#225;geno, que es el saco peric&#225;rdico. El pericardio tiene gran capacidad de adaptaci&#243;n en situaciones de dilataci&#243;n cr&#243;nica ventricular, cuando hay aumento de complacencia.</p>
      <p>Al contrario, en las situaciones de dilataci&#243;n aguada de cualquiera de los ventr&#237;culos, como en algunos casos de insuficiencia mitral y cor pulmonale, el aumento de la presi&#243;n diast&#243;lica y la eventual congesti&#243;n pulmonar pueden presentar componente de la fuerza de contenci&#243;n impuesta por el saco peric&#225;rdico.</p>
      <p>
        <bold>Interacci&#243;n entre los ventr&#237;culos</bold>
      </p>
      <p>Aumentos agudos del volumen y de la presi&#243;n de uno de los ventr&#237;culos pueden afectar la complacencia del otro ventr&#237;culo. Con todo, esta interacci&#243;n es muy acentuada en ausencia del pericardio.</p>
      <p>
        <bold>Presentaci&#243;n cl&#237;nica y diagn&#243;stico</bold>
      </p>
      <p>La presentaci&#243;n cl&#237;nica es similar a la de insuficiencia card&#237;aca sist&#243;lica. Se ha descrito que, en la ICFEN, el cuadro de disnea se instala en forma m&#225;s aguda y la respuesta a las intervenciones tambi&#233;n es m&#225;s r&#225;pida<sup>32,33</sup>. En un estudio europeo que incluy&#243; pacientes internados con IC, se observ&#243; que la prevalencia de ICFEN fue del 40%. Esa entidad fue asociada de forma significativa e independiente con el sexo femenino, edad avanzada y presencia de fibrilaci&#243;n atrial (FA). La insuficiencia card&#237;aca sist&#243;lica fue asociada con clase funcional (NYHA) m&#225;s avanzada, cardiomegalia, presencia de tercer ruido, edema agudo del pulm&#243;n y bloqueo de rama izquierda<sup>32</sup>. El <xref ref-type="fig" rid="c1-body2">Cuadro 1</xref> muestra las diferencias entre ICFEN e IC con FE reducida.</p>
      <fig id="c1-body2">
        <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf03-es.jpg"/></fig>
      <p>La insuficiencia card&#237;aca secundaria a la DD se entiende hoy como la entidad de las comorbilidades. Varios estudios mostraron que pacientes con ICFEN tienen hipertensi&#243;n arterial (HAS), isquemia mioc&#225;rdica, Diabetes mellitus (DM), obesidad y disfunci&#243;n tiroidea. La asociaci&#243;n con enfermedades intr&#237;nsecas del coraz&#243;n es menos frecuente<sup>34,35</sup>.</p>
      <p>Los &#237;ndices capaces de cuantificar directamente la funci&#243;n diast&#243;lica son obtenidos de forma invasiva. El primero de ellos es la constante de tau, medida ampliamente utilizada de la tasa de relajaci&#243;n del ventr&#237;culo izquierdo<sup>36,37</sup>. El segundo indicador derecho es la medida de la complacencia ventricular, que requiere el registro simult&#225;neo de la presi&#243;n y del volumen de la c&#225;mara<sup>12</sup>. El ventr&#237;culo menos complaciente es aquel que presenta mayor elevaci&#243;n de la presi&#243;n para una variaci&#243;n de volumen dada. Es claro que los dos &#237;ndices son inviables para uso rutinario en la pr&#225;ctica cl&#237;nica.</p>
      <p>Los marcadores disponibles en la pr&#225;ctica cl&#237;nica reflejan, de hecho, un conjunto de variables que indirectamente eval&#250;an la funci&#243;n diast&#243;lica. Aunque los indicadores m&#225;s utilizados para la evaluaci&#243;n de la funci&#243;n diast&#243;lica se obtengan por medio del ecocardiograma, el diagn&#243;stico debe seguir las recomendaciones de la Sociedad Brasile&#241;a de Cardiolog&#237;a para el diagn&#243;stico de IC de cualquier et&#237;ologia<sup>38</sup>. Es decir, frente a la sospecha cl&#237;nica de IC, resulta necesaria la realizaci&#243;n del electrocardiograma, RX de t&#243;rax y, si fuera posible, la determinaci&#243;n del BNP. Si se detectaran alteraciones en esos ex&#225;menes de laboratorio, se solicita el ecocardiograma que permitir&#225; confirmar o descartar el diagn&#243;stico de ICFEN. Vale destacar, por la facilitad de obtenci&#243;n del examen, que el RX de t&#243;rax, aunque no sea espec&#237;fico, puede auxiliar en la sospecha del diagn&#243;stico. Es decir, frente a un caso de IC, la presencia de cardiomegalia aumenta la chance de disfunci&#243;n sist&#243;lica. Al contrario, si el &#225;rea card&#237;aca fuera normal, aumenta la probabilidad de ICFEN.</p>
      <p>El ecocardiograma tiene mayor exactitud y permite el diagn&#243;stico de alteraciones estructurales, como la hipertrofia y &#225;reas de hipocinesias, frecuentemente asociadas con disfunci&#243;n diast&#243;lica. La hipocinesia regional es fuertemente sugestiva de isquemia mioc&#225;rdica, con efectos perjudiciales sobre la relajaci&#243;n, explicando la asociaci&#243;n. Adem&#225;s de ello, el Doppler pulsado permite el an&#225;lisis del flujo diast&#243;lico transmitral, de la cual derivan los &#237;ndices primarios de funci&#243;n y la estratificaci&#243;n de la gravedad de la disfunci&#243;n<sup>39</sup>. Como se describiera anteriormente, este flujo depende del gradiente de presi&#243;n transvalvular. En condiciones normales, este gradiente es m&#225;ximo inmediatamente despu&#233;s de la apertura de la v&#225;lvula mitral, teniendo en vista la plenitud del volumen del atrio izquierdo y la baja presi&#243;n intraventricular, debido a la relajaci&#243;n mioc&#225;rdica y al peque&#241;o volumen residual en la c&#225;mara. En ese momento, la velocidad de flujo es m&#225;xima, constituyendo la onda E.</p>
      <p>Sigue el per&#237;odo de gradiente transvalvular reducido, con flujo casi nulo (di&#225;stasis). En la contracci&#243;n atrial se genera un nuevo gradiente y flujo, correspondiente a la onda A. El cociente E/A, uno de los &#237;ndices primarios para el estudio de la di&#225;stole, permanece 1 (<xref ref-type="fig" rid="es_19f03-body2">Figura 3, - A</xref>). Estando la relajaci&#243;n mioc&#225;rdica perjudicada, hay reducci&#243;n del gradiente transvalvular, al inicio de la di&#225;stole, con disminuci&#243;n de la onda E. La consecuencia es el perjuicio en el vaciado auricular, la contracci&#243;n atrial es m&#225;s vigorosa y la onda A crece, reduciendo la raz&#243;n E/A (<xref ref-type="fig" rid="es_19f03-body2">Figura 3, B</xref>). Este patr&#243;n de flujo es caracter&#237;stico de DD leve o grado I. Si hubiera perjuicio adicional de la funci&#243;n, la presi&#243;n en el atrio izquierdo crece, recomponiendo los gradientes de presi&#243;n transvalvular durante la di&#225;stole, aunque en niveles mayores de presi&#243;n y en presencia de s&#237;ntoma de intolerancia a los esfuerzos. En esa etapa, la DD es grado II o moderado (<xref ref-type="fig" rid="es_19f03-body2">Figura 3, C</xref>).</p>
      <p content-type="html"><fig id="es_19f03-body2"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/944N6f3NJtJyn9pC7Dnh4yL/0f7092c3f8a8880e091e7d275a703444b05a7d81.jpg"/><graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf04-es.jpg"/></fig>&#13;
</p>
      <p>En los pacientes en que la presi&#243;n diast&#243;lica del VI es suficientemente alta como para restringir el flujo transvalvular durante la contracci&#243;n atrial, la presi&#243;n elevada del AI permite apenas un flujo diast&#243;lico inicial de alta velocidad y corta duraci&#243;n, reduciendo notablemente la velocidad de flujo al final de la di&#225;stole (<xref ref-type="fig" rid="es_19f03-body2">Figura 3, D</xref>). Este patr&#243;n, llamado restrictivo o grado III, es grave y causa intolerancia a los esfuerzos leves. Cuando la maniobra de Valsalva no alivia esta alteraci&#243;n, se define la DD como grado IV, tambi&#233;n grave. Los otros dos indicadores primarios derivados del Doppler pulsado son el tiempo de desaceleraci&#243;n de la onda E y el tiempo de relajaci&#243;n isovolum&#233;trica.</p>
      <p>El an&#225;lisis del flujo en las venas pulmonares por medio de Doppler pulsado permite la evaluaci&#243;n indirecta de la presi&#243;n atrial que, en ausencia de valvulopat&#237;a mitral, corresponde a la presi&#243;n diast&#243;lica del VI. En resumen, las presiones normales en el AI permiten un flujo constante a partir de las venas pulmonares, excepto durante la contracci&#243;n atrial, cuando hay un peque&#241;o flujo reverso. Cuando este patr&#243;n se altera, es posible diagnosticar disfunci&#243;n diast&#243;lica.</p>
      <p>M&#225;s recientemente, fueron incluidos en la evaluaci&#243;n de la funci&#243;n diast&#243;lica otros &#237;ndices valiosos, como las medidas de la velocidad de movimiento del tejido anular mitral (Doppler tisular) y la estimativa del volumen de la fracci&#243;n del AI. Actualmente, estas variables, conjuntamente con la evaluaci&#243;n del volumen ventricular y de la masa mioc&#225;rdica, son consideradas fundamentales para la definici&#243;n del diagn&#243;stico y de la estratificaci&#243;n de la gravedad de la ICFEN<sup>15,39</sup>. Es importante resaltar que las recomendaciones europeas, americana y brasile&#241;a sobre este tema incorporan las alteraciones fisiol&#243;gicas propias del envejecimiento en los valores de los &#237;ndices primarios y de aquellos derivados del Doppler tisular<sup>14,15,38</sup>. Con ello, la exactitud del m&#233;todo en identificar individuos de mayor riesgo deber&#225; ser mejorada.</p>
      <p>Un aspecto relevante a ser considerado por el cl&#237;nico que asiste al paciente con ICFEN es la labilidad de varios &#237;ndices de funci&#243;n diast&#243;lica con relaci&#243;n a la actividad f&#237;sica. Como los ex&#225;menes se realizan con los pacientes en reposo, puede haber discrepancia entre la intensidad de la disnea de esfuerzo y el resultado de la estratificaci&#243;n del grado de la DD. En estos casos, la evaluaci&#243;n ecocargiogr&#225;fica puede realizarse inmediatamente despu&#233;s del esfuerzo f&#237;sico<sup>39</sup>. La discusi&#243;n detallada y t&#233;cnica sobre estos indicadores interesa m&#225;s al especialista en ecocardiograma y no es el foco de la presente revisi&#243;n. Con todo, es preciso reforzar el hecho de que permanece en debate en la bibliograf&#237;a la confiabilidad de los &#237;ndices no invasivos, especialmente la raz&#243;n velocidad de flujo/velocidad de movimiento del anillo mitral, para estimar la presi&#243;n de llenado del ventr&#237;culo izquierdo<sup>40-42</sup>.</p>
      <p>El diagn&#243;stico definitivo de disfunci&#243;n diast&#243;lica requiere tres criterios seg&#250;n el concepto actual<sup>15</sup>: dos mayores y uno confirmatorio. La evidencia inequ&#237;voca de DD y la evidencia objetiva de funci&#243;n sist&#243;lica preservada (FE mayor que 0,50 en las 72h de agudizaci&#243;n de la IC) constituyen criterios mayores. La evidencia objetiva de ICD constituye criterio confirmatorio. La evaluaci&#243;n objetiva de DD podr&#237;a ser derivada del ecocardiograma, seg&#250;n Paulos et al<sup>15</sup>, o de medida directa invasiva, seg&#250;n Vasan y Levy<sup>43</sup>.</p>
      <p>En 2001, Zile et al<sup>44</sup> evaluaron, por medio de cateterismo card&#237;aco, la funci&#243;n diast&#243;lica de pacientes con ICD y verificaron que todos presentaban DD. Zile et al<sup>44</sup> cuestionaron la necesidad de ese tercer criterio. En 2005, Yturralde y Gaasch<sup>45</sup> propusieron que los dos primeros criterios fueran considerados mayores, siempre que el tama&#241;o del VI fuera normal y que el tercer criterio fuera apenas confirmatorio, asociado a la presencia de HVI y AI aumentado, en ausencia de valvulopat&#237;a mitral y FA<sup>45</sup>.</p>
      <p>De hecho, estas se&#241;ales indirectas est&#225;n siendo valorizadas como marcadores de DD. Pritchett et al<sup>46</sup> utilizaron los valores de volumen de AI en m&#225;s de 2.000 individuos, con edad igual o superior a 45 a&#241;os, incluidos en el Estudio del Condado de Olmsted, y observaron que esa variable tiene valor pron&#243;stico en la predicci&#243;n de mortalidad en 5 a&#241;os<sup>46</sup>. Lester et al<sup>47</sup> defendieron la posici&#243;n de que el volumen del AI guardar&#237;a con la DD la misma relaci&#243;n que la hemoglobina glicosilada con la DM.</p>
      <p>Con todo, pueden ocurrir muchas dificultades en el diagn&#243;stico, como la imposibilidad de obtener el ecocardiograma, o s&#237;ntomas no espec&#237;ficos y se&#241;ales poco evidentes. Frecuentemente, los pacientes presentan enfermedad pulmonar asociada o son obesos; son a&#241;osos con varias comorbilidades o con dificultades de comunicaci&#243;n. En fin, hay una serie de circunstancias cl&#237;nicas que impide la asociaci&#243;n directa entre una queja de limitaci&#243;n f&#237;sica o disnea con el diagn&#243;stico de IC.</p>
      <p>En esos casos, un marcador de laboratorio que se presenta y que puede ser &#250;til es el nivel plasm&#225;tico del BNP (<italic>brain natriuretic factor</italic>). Este p&#233;ptido natriur&#233;tico se almacena en el miocardio ventricular, y se libera cuando la pared sufre estiramiento. Presenta menor influencia de las variaciones de la presi&#243;n en el atrio, y por ello refleja mejor la disfunci&#243;n ventricular que el p&#233;ptido natriur&#233;tico atrial.</p>
      <p>Muchos estudios mostraron la utilidad del BNP como marcador diagn&#243;stico y pron&#243;stico en la IC sist&#243;lica<sup>48,49</sup>. En la IC diast&#243;lica, las evidencias no son tan contundentes, pero empiezan a aparecer. El nivel de BNP con mayor exactitud para detectar disfunci&#243;n diast&#243;lica es 60-90 pg/ml<sup>50</sup>. Adem&#225;s de ello, el nivel de BNP es mayor cuanto m&#225;s grave es la disfunci&#243;n y aumenta todav&#237;a m&#225;s en presencia de se&#241;ales cl&#237;nicas de IC. El consenso actual entiende que el BNP es todav&#237;a m&#225;s importante para descartar el origen card&#237;aco en pacientes atendidos con disnea en reposo<sup>38</sup>.</p>
      <p>
        <bold>Tratamiento</bold>
      </p>
      <p>Pocos estudios evaluaron desenlaces cl&#237;nicos en pacientes con ICD y que fueron tratados con diferentes clases de drogas. Y el hecho es que ninguno de ellos mostr&#243; cambio en la historia natural del s&#237;ndrome.</p>
      <p>El primer gran estudio, y bastante conocido, fue el CHARM-preserved<sup>51</sup>, publicado en 2003 y destinado a evaluar el efecto del candesart&#225;n en 025 pacientes con IC y FE superior al 40%. La poblaci&#243;n que compon&#237;a el estudio era predominantemente masculina y con intervalo de edades inferior a la que m&#225;s presenta ICD. En este estudio no hubo reducci&#243;n de la mortalidad, aunque el n&#250;mero de internaciones por IC haya sido significativamente menor.</p>
      <p>El estudio PEP-CHF<sup>52</sup> incluy&#243; pacientes m&#225;s a&#241;osos, con edad superior a 70 a&#241;os y FE &gt; 45%, y fall&#243; en mostrar reducci&#243;n en la mortalidad con el uso prolongado de perindopril. Otros estudios tampoco manifestaron efectos relevantes con el uso de nebivolol<sup>53</sup> y con digoxina<sup>54</sup>. Recientemente, el estudio I PRESERVED, incluyendo pacientes con m&#225;s de 60 a&#241;os y FE &gt; 60%, mostr&#243; que el ibersartan no disminuy&#243; el riesgo de desenlace compuesto muerte y hospitalizaci&#243;n por causa cardiovascular<sup>55</sup>. El estudio TOPCAT, con t&#233;rmino previsto para 2011, pretende evaluar los efectos de la espironolactona en los desenlaces cl&#237;nicos de 4.500 pacientes con funci&#243;n sist&#243;lica preservada.</p>
      <p>En este contexto, actualmente los objetivos principales en el tratamiento de la ICFEN son controlar los s&#237;ntomas por la reducci&#243;n de la congesti&#243;n venosa y de la frecuencia card&#237;aca. El control del ritmo tambi&#233;n se considera v&#225;lido en pacientes seleccionados, sea por medio de cardioversi&#243;n el&#233;ctrica y/o qu&#237;mica, o marcapaso secuencial.</p>
      <p>Otras metas a ser alcanzadas son los controles de las comorbilidades asociadas con DD, como tratamiento de la isquemia mioc&#225;rdica y de la HAS, prevenci&#243;n y reversi&#243;n de la hipertrofia ventricular izquierda, atenuaci&#243;n o prevenci&#243;n de fibrosis mioc&#225;rdica.</p>
      <p>Es necesario recordar que esos pacientes con DD son t&#237;picamente a&#241;osos y con cavidad ventricular de tama&#241;o normal. Por lo tanto, medidas como diur&#233;ticos y vasodilataci&#243;n pueden tener efecto desproporcionado en la PA. Los cuidados espec&#237;ficos incluyen el monitoreo de la presi&#243;n arterial, de la funci&#243;n renal y de se&#241;ales de hipoflujo cerebral. Incluyen tambi&#233;n estimular la adherencia al tratamiento y cambios de h&#225;bitos de vida (alimentaci&#243;n, actividad f&#237;sica y tabaquismo, principalmente), teniendo en vista que estos pacientes son medicados simult&#225;neamente con varias clases de drogas.</p>
      <p>En adultos mayores, la conducta debe obedecer a algunos criterios especiales. Se orienta iniciar con una clase de droga e ir agregando otras clases, siempre una por vez. No hay evidencia de que la dosis objetivo de cada clase deba ser alcanzada, como ocurre en la IC sist&#243;lica.</p>
      <p>As&#237;, se recomienda:</p>
      <disp-quote>
        <p>&#149; Iniciar diur&#233;ticos y betabloqueadores con cautela;</p>
        <p>&#149; Si la IC persistiera, agregar inhibidor de enzima de conversi&#243;n de la angiotensina (IECA), o bloqueador del receptor de angiotensina (BRA), si hubiera intolerancia a IECA;</p>
        <p>&#149; Agregar dinitrato de isosorbida e hidralazina, si fuera necesario;</p>
        <p>&#149; Agregar antagonistas de los canales de calcio, si fuera necesario;</p>
        <p>&#149; Evitar el uso de digit&#225;licos, en ausencia de FA.</p>
      </disp-quote>
      <p>El <xref ref-type="fig" rid="es_19c02-body2">Cuadro 2</xref> resume las principales opciones terap&#233;uticas y respectivos niveles de evidencia en los casos de ICFEN, seg&#250;n la III Directriz Brasile&#241;a de Insuficiencia Card&#237;aca Cr&#243;nica<sup>38</sup>. Observar que los niveles de evidencia para cada opci&#243;n terap&#233;utica todav&#237;a no son elevados Por lo tanto, en esos pacientes, es importante la individualizaci&#243;n del tratamiento.</p>
      <p content-type="asset">
        <fig id="es_19c02-body2">
          <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf05-es.jpg"/></fig>
      </p>
      <p>
        <bold>Pron&#243;stico</bold>
      </p>
      <p>Estudio de pacientes con ICFEN mostr&#243; que la sobrevida en 1, 3 y 5 a&#241;os fue, respectivamente, 84%, 67% y 51%<sup>32</sup>. En otro estudio, el impacto de la gravedad de la DD fue evaluada en 2.042 adultos con m&#225;s de 45 a&#241;os, siendo el 95% asintom&#225;ticos. Se observ&#243; que la mortalidad fue significativamente mayor en aquellos con ecocardiograma manifestando DD grados II y III<sup>17</sup>. Estos resultados fueron similares a los descritos por Pritchett et al<sup>46</sup>. Adem&#225;s de ello, esos autores observaron que el volumen del AI present&#243; valor pron&#243;stico similar al de la gravedad de la DD. En pacientes con insuficiencia coronaria cr&#243;nica, la mortalidad cardiovascular en tres a&#241;os fue significativamente mayor (6%) en los casos con DD moderada o grave, al compararlos con alteraci&#243;n leve (3,6%) o di&#225;stole normal (1,1%)<sup>56</sup>.</p>
      <p>Jones et al<sup>34</sup> evaluaron la mortalidad en tres a&#241;os de una cohorte de casi 1.000 pacientes con ICFEN y FE &gt; 0,45, participantes en el ensayo cl&#237;nico DIG. Entre las 18 variables analizadas, las que se asociaron con muerte fueron: filtraci&#243;n glomerular, clase funcional de NYHA, sexo masculino, edad avanzada, &#237;ndice cardiotor&#225;cico, presencia de DM, necesidad de vasodilatadores o de diur&#233;ticos. En funci&#243;n de esas variables, los pacientes recibieron scores de riesgo y aquellos con los mayores escores (cuartil 75) presentaron mortalidad del 50% en el per&#237;odo. Por lo tanto, el paciente con ICFEN necesita ser evaluado por medio de un conjunto amplio de variables cl&#237;nicas y de laboratorio, que extrapola la definici&#243;n del grado de la disfunci&#243;n o de otras variables ecocardiogr&#225;ficas.</p>
      <p>
        <bold>Perspectivas</bold>
      </p>
      <p>Finalmente, un aspecto que est&#225; cobrando nuevamente espacio en la bibliograf&#237;a es el cuestionamiento sobre el papel de la disfunci&#243;n sist&#243;lica en los cuadros de ICFEN. En el estudio de Yu et al, incluyendo pacientes normales y pacientes don DD o IC sist&#243;lica, se mostr&#243; que el &#237;ndice funci&#243;n sist&#243;lica evaluado por Doppler tisular reduc&#237;a progresivamente a medida que empeoraba el grado de disfunci&#243;n diast&#243;lica<sup>57</sup>. Este resultado sugiere que pacientes con DD tambi&#233;n tienen disfunci&#243;n sist&#243;lica, aun sin manifestaci&#243;n cl&#237;nica o con la FE preservada.</p>
      <p>Otro estudio que utiliz&#243; el an&#225;lisis de la funci&#243;n ventricular por medio del <italic>strain rate</italic>, identific&#243; asociaci&#243;n directa entre pico de contracci&#243;n y pico de relajaci&#243;n, en individuos normales o con diferentes cardiopat&#237;as, sugiriendo la interdependencia de las dos fases del ciclo card&#237;aco<sup>58</sup>.</p>
      <p>Un estudio m&#225;s reciente, realizado por Yu et al<sup>59</sup>, analiz&#243; a 56 pacientes con ICFEN y mostr&#243; que varios &#237;ndices ecocardiogr&#225;ficos de funci&#243;n sist&#243;lica, obtenidos en reposo, eran significativamente menores al compararlos a 27 individuos saludables<sup>59</sup>. Adem&#225;s de ello, en el grupo con ICFEN, estos &#237;ndices no aumentaban con el ejercicio. Este estudio refuerza la hip&#243;tesis de que la ICFEN no es un desorden involucrando s&#243;lo la di&#225;stole, aun cuando la FE est&#233; preservada. Tambi&#233;n ofrece subsidios para la afirmativa de Leste et al<sup>47</sup>: "Tal vez, en un futuro pr&#243;ximo, disfunci&#243;n sist&#243;lica y disfunci&#243;n diast&#243;lica no ser&#225;n interpretadas cl&#237;nicamente como t&#233;rminos dicot&#243;micos. Ser&#225;n entendidas, simplemente, como disfunci&#243;n card&#237;aca."</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
      <p>1. Minist&#233;rio da Sa&#250;de. DATASUS. Informa&#231;&#245;es de sa&#250;de. [Acesso em 2009 fev. 10]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://tabnet.datasus.gov.br">http://tabnet.datasus.gov.br</ext-link></p>
      <p>2. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993; 22 (Suppl A): 6A-13A.</p>
      <p>3. Sanderson JE. Heart failure with a normal ejection fraction. Heart. 2007; 93: 155-8.</p>
      <p>4. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II. Circulation. 2002; 105: 1503-8.</p>
      <p>5. Roelandt JRTC. On-invasive assessment of left ventricular diastolic (dys) function and filling pressure. Heart Views. 2001; 2 (3): September-November.</p>
      <p>6. Parmley WW, Brutsaert DL, Sonnenblick EH. Effects of altered loading on contractile events in isolated cat papillary muscle. Circ Res. 1969; 24 (4): 521-32.</p>
      <p>7. Grossman W, McLaurin LP, Rolett EL. Alterations in left ventricular relaxation and diastolic compliance in congestive cardiomyopathy. Cardiovasc Res. 1979; 13 (9): 514-22.</p>
      <p>8. Dodek A, Kassebaum DG, Bristow JD. Pulmonary edema in coronary-artery disease without cardiomegaly: paradox of the stiff heart. N Engl J Med. 1972; 286: 1347-50.</p>
      <p>9. Brutsaert DL, Rademakers FE, Sys SU. Triple control of relaxation: implications in cardiac disease. Circulation. 1984; 69: 190-6.</p>
      <p>10. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA. 1994; 27: 1276-80.</p>
      <p>11. Gaasch WH, Zile MR. Left ventricular dysfunction and diastolic heart failure. Annu Rev Med. 2004; 55: 373-94.</p>
      <p>12. Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation. 2005; 111: 2306-12.</p>
      <p>13. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss C, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999; 33: 1948-55.</p>
      <p>14. Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in heart failure. J Am Coll Cardiol. 2007; 50: 381-96.</p>
      <p>15. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European Society of Cardiology. Eur Heart J. 2007; 28: 2539-50.</p>
      <p>16. Pfeffer M, Swedberg K, Granger C, Held P, McMurray J, Michelson E, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759-66.</p>
      <p>17. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289: 194-202.</p>
      <p>18. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Eng J Med. 2006; 355: 251-9.</p>
      <p>19. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J. 2004; 25 (14): 1214-20.</p>
      <p>20. Peyster E, Norman J, Domanski M. Prevalence and predictors of heart failure with preserved systolic function: community hospital admissions of a racially and gender diverse elderly population. J Card Fail. 2004; 10: 49-54.</p>
      <p>21. Aronow WS. Epidemiology, pathophisiology, prognosis, and treatment of systolic and diastolic heart failure. Cardiol Rev. 2006; 14 (3): 108-24.</p>
      <p>22. Moutinho MA, Colucci FA, Alcoforado V, Tavares LR, Rachid MB, Rosa ML, et al. Heart failure with preserved ejection fraction and systolic dysfunction in the community. Arq Bras Cardiol. 2008; 90: 132-7.</p>
      <p>23. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res. 2004; 94 (12): 1533-42.</p>
      <p>24. Hay I, Rich J, Ferber P, Burkhoff D, Maurer MS. Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure. Am J Physiol Heart Circ Physiol. 2005; 288: H1203-H1208.</p>
      <p>25. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005; 289: H501-H512.</p>
      <p>26. De Stefano LM, Matsubara LS, Matsubara BB. Myocardial dysfunction with increased ventricular compliance in volume overload hypertrophy. Eur J Heart Fail. 2006; 8: 784-9.</p>
      <p>27. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005; 111: 774-81.</p>
      <p>28. Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004; 94: e61-e70.</p>
      <p>29. Matsubara LS, Matsubara BB, Okoshi MP, Cicogna AC, Janicki JS. Alterations in myocardial collagen affect rat papillary muscle function. Am J Physiol Heart Cic Physiol. 2000; 279: H1534-H1539.</p>
      <p>30. Hein S, Amon E, Kostin S, Sch&#246;nburg M, El&#228;sser A, Polyakova V, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003; 107: 984-91.</p>
      <p>31. Matsubara LS, Narikawa S, Ferreira ALA, Paiva SAR, Zornoff LAM, Matsubara BB. Remodela&#231;&#227;o mioc&#225;rdica na sobrecarga cr&#244;nica de press&#227;o ou de volume no cora&#231;&#227;o de ratos. Arq Bras Cardiol. 2006; 86: 126-30.</p>
      <p>32. Varela-Roman A, Grigorian L, Barge E. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart. 2005; 91: 489-94.</p>
      <p>33. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function. A report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006; 47: 76-84.</p>
      <p>34. Jones RC, Francis GS, Lauer MS. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group Trial. J Am Coll Cardiol. 2004; 44: 1025-9.</p>
      <p>35. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006; 355: 260-9.</p>
      <p>36. Yamamoto K, Masuyama T, Doi Y, Naito J, Mano T, Kondo H, et al. Noninvasive assessment of LV relaxation using continuous wave Doppler aortic regurgitant velocity curve: its comparative value to the mitral regurgitation method. Circulation. 1995; 91: 192-200.</p>
      <p>37. Honda Y, Yokota Y, Yokoyama M. Evaluation of left ventricular relaxation using the continuous-wave Doppler velocity profile of aortic regurgitation: noninvasive measurement of left ventricular negative dP/dt and time constant. Clin Cardiol. 1996; 19: 709-15.</p>
      <p>38. Sociedade Brasileira de Cardiologia. III Diretriz brasileira de insufici&#234;ncia card&#237;aca cr&#244;nica. Arq Bras Cardiol. 2009; 93: 1-71.</p>
      <p>39. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009; 22 (2): 107-33.</p>
      <p>40. Mesquita ET, Jorge AJL. Insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o normal - novos crit&#233;rios diagn&#243;sticos e avan&#231;os fisiopatol&#243;gicos. Arq Bras Cardiol. 2009; 93 (2): 180-7.</p>
      <p>41. Little WC, Oh JK. Echocardiographic evaluation of diastolic function can be used to guide clinical care. Circulation. 2009; 120 (9): 802-9.</p>
      <p>42. Tsh&#246;pe C, Paulus. Is echocardiographic evaluation of diastolic function useful in determining clinical care? Doppler echocardiography yields bubious estimates of left ventricular diastolic pressures. Circulation. 2009; 120 (9): 810-20.</p>
      <p>43. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diastolic criteria. Circulation. 2000; 101: 2118-21.</p>
      <p>44. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001; 104: 779-82.</p>
      <p>45. Yturralde FR, Gaasch WH. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis. 2005; 47: 314-9.</p>
      <p>46. Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield M. Diastolic dysfunction and left atrial volume. J Am Coll Cardiol. 2005; 45: 87-92.</p>
      <p>47. Lester SJ, Tajik J, Nishimura RA, Oh JK, Khandheria BK, Seward JB. Unlocking the mysteries of diastolic function. J Am Coll Cardiol. 2008; 51: 679-89.</p>
      <p>48. Clerico A, Iervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest. 1998; 21 (3): 170-9.</p>
      <p>49. Omland T, Aakvaag A, Bonarjee VVS, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996; 93 (11): 1963-9.</p>
      <p>50. Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, et al Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001; 111: 274-9.</p>
      <p>51. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray J, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362: 777-81.</p>
      <p>52. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27: 2238-45.</p>
      <p>53. Shibata MC, Flather MD, B&#246;hm M, Borbola J, Cohen-Solal A, Dumitrascu D, et al. Study of the effects of nebivolol intervention on outcomes and rehospitalisation in seniors with Heart Failure (SENIORS). Rationale and design. Int J Cardiol. 2002; 86: 77-85.</p>
      <p>54. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects on digoxin on morbitity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006; 114: 397-403.</p>
      <p>55. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359: 1-12.</p>
      <p>56. Ren X, Ristow B, Na B, Ali S, Schiller NB, Whooley MA. Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction ambulatory patients with coronary heart disease. Am J Cardiol. 2007; 99: 1643-7.</p>
      <p>57. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SWL. Progression of systolic abnormalities in patients with "isolated" diastolic heart failures and diastolic dysfunction. Circulation. 2002; 105: 1195-201.</p>
      <p>58. Takamura T, Dohi K, Fujimoto N, Kurita T, Kato S. Coupling of left ventricular relaxation to systolic contraction in normal, hypertrophied and dilated myocardium quantified by speckel-tracking global strain and strain rate imaging. Circulation. 2007; 116: 708-9.</p>
      <p>59. Yu TT, Wenzelburger F, Lee E, Heatlie G, Leyva F, Patel K, et al. The pathophysiology of heart failure with normal ejection fraction. J Am Coll Cardiol. 2009; 54: 36-46.</p>
      <p>
        <fn id="end-body2" fn-type="corresp">
          <p>Correspondencia:</p>
          <p> Meliza Goi Roscani</p>
          <p> R. Doutor Jos&#233; Augusto de Arruda Botelho, 70 - Jardim Maria Lu</p>
          <p> 17203-030 - Ja&#250;, SP - Brasil</p>
          <p> E-mail: </p>
          <p><email xlink:href="meliza10@cardiol.br">meliza10@cardiol.br</email>, </p>
          <p>
            <email xlink:href="meliza10@hotmail.com">meliza10@hotmail.com</email>
          </p>
        </fn>
      </p>
      <p>Art&#237;culo recibido el 27/07/09; revisado recibido el 04/09/09; aceptado el 21/09/09.</p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Heart failure with normal ejection fraction</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>Heart failure with normal ejection fraction (HFNEF) is a complex syndrome that has been broadly studied since the last decade. It is caused by diastolic ventricular dysfunction demonstrated by complementary methods, such as hemodynamic study or echocardiogram, in the presence of a normal ejection fraction (EF). It affects primarily elderly individuals with comorbidities, such as systemic arterial hypertension, coronary failure and obesity. The physiopathological mechanisms are complex and multifactorial, involving the myocardial passive stiffness, the ventricular geometry, the pericardial restraint and the interaction between the ventricles. The main objectives of the treatment were to decrease the pulmonary venous congestion and the heart rate and control the comorbidities. There is no strong evidence that the use of specific medications, such as the angiotensin-converting enzyme inhibitors or beta-blockers can influence mortality. The poorer prognostic factors include advanced age, presence of kidney dysfunction, diabetes, functional class III and IV (NYHA) and advanced-stage diastolic dysfunction, with a restrictive pattern of ventricular filling. Another aspect that has been increasingly cited in the literature is the analysis of the role of the systolic function in HFNEF cases. All these aspects are analyzed in detail in the present review.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart failure</kwd>
        <kwd>diastole</kwd>
        <kwd>cardiomegaly</kwd>
        <kwd>echocardiography</kwd>
        <kwd>compliance</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>REVIEW ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Heart failure with normal ejection fraction</bold>
          </label>
          <p>
            <bold>Meliza Goi Roscani; Luiz Shiguero Matsubara; Beatriz Bojikian Matsubara</bold>
          </p>
        </fn>
      </p>
      <p>Faculdade de Medicina de Botucatu - UNESP, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>Heart failure with normal ejection fraction (HFNEF) is a complex syndrome that has been broadly studied since the last decade. It is caused by diastolic ventricular dysfunction demonstrated by complementary methods, such as hemodynamic study or echocardiogram, in the presence of a normal ejection fraction (EF). It affects primarily elderly individuals with comorbidities, such as systemic arterial hypertension, coronary failure and obesity. The physiopathological mechanisms are complex and multifactorial, involving the myocardial passive stiffness, the ventricular geometry, the pericardial restraint and the interaction between the ventricles. The main objectives of the treatment were to decrease the pulmonary venous congestion and the heart rate and control the comorbidities. There is no strong evidence that the use of specific medications, such as the angiotensin-converting enzyme inhibitors or beta-blockers can influence mortality. The poorer prognostic factors include advanced age, presence of kidney dysfunction, diabetes, functional class III and IV (NYHA) and advanced-stage diastolic dysfunction, with a restrictive pattern of ventricular filling.</p>
      <p> Another aspect that has been increasingly cited in the literature is the analysis of the role of the systolic function in HFNEF cases. All these aspects are analyzed in detail in the present review.</p>
      <p><bold>Key words:</bold> Heart failure; diastole; cardiomegaly; echocardiography; compliance.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Heart failure (HF) is a complex syndrome characterized by intolerance to physical exertion, fluid retention and congestive phenomena, which after symptom onset, presents high rates of morbimortality.</p>
      <p>Its prevalence is increasing worldwide and it is estimated that there will be 5 million cases of HF in Brazil by the year 2025<sup>1</sup>. The accumulated risk of developing HF during a decade is higher in the elderly population than in younger individuals<sup>2</sup>. Therefore, in elderly individuals with classic signs or symptoms of HF, the intolerance to physical exercises is frequently due to the increased pressure in the left atrium, although the EF remains within the normal limits.</p>
      <p>This condition corresponds to diastolic heart failure (DHF). This entity has been the subject of discussion in the last decade and several concepts have been updated, justifying the present review.</p>
      <p>
        <bold>Terminology</bold>
      </p>
      <p>There is a controversy in the literature regarding the most adequate terminology for this clinical condition: "diastolic heart failure" or "HF with normal ejection fraction". Those who defend the term "HF with preserved systolic function" assert that this more descriptive form prevents confusion or a misdiagnosis, considering that the diastolic dysfunction is present in almost all cases of HF<sup>3</sup>.</p>
      <p>The authors that defend the term "diastolic dysfunction" assert that, by specifying the term "diastolic", it is implicit that a significant systolic dysfunction is excluded and that the congestive phenomenon depends on the diastolic dysfunction (DD). They also state that the term "heart failure with preserved systolic function" does not allow the differentiation from cases with mitral valvulopathy with normal EF and that the HF is not due to the diastolic dysfunction<sup>4</sup>.</p>
      <p>Currently, several authors have substituted the term "preserved systolic function" by "normal EF", understanding that patients with diastolic HF can present some degree of systolic dysfunction. In the literature, these terms are used as synonyms. This review will use preferentially the term "HF with normal EF", or HFNEF, as it is more descriptive.</p>
      <p>
        <bold>Historical aspects and concepts</bold>
      </p>
      <p>According to Roelandt, the first association between myocardial relaxation and ventricular function was described in 1923 by Yendell Handerson, who affirmed that the myocardial relaxation was as important as its contraction<sup>5</sup>. He exemplified that an elderly patient, with delayed myocardial relaxation, could present intolerance to physical exertion. Therefore, what would later be described as heart failure with normal ejection fraction (HFNEF) had just been described.</p>
      <p>However, the concept only received attention in the 60s<sup>6</sup> and the in the following decade, with studies associating myocardial ischemia with left ventricular (LV) diastolic dysfunction<sup>7,8</sup>.</p>
      <p>In 1984, Brutsaert described his theory on the triple control of myocardial relaxation<sup>9</sup>, which would depend on pre-load, on muscle inactivation and the uniformity of the inactivation in time and space.</p>
      <p>Gaasch defined the term "diastolic dysfunction" in 1994, as the "inability of the heart to accommodate the blood volume during diastole at low pressures; the ventricular filling is delayed or incomplete and the atrial pressure increases, causing pulmonary or systemic congestion"<sup>10</sup>. Ten years later, in 2004, the same author<sup>11</sup> redefined the entity, writing: "The diastolic dysfunction can occur regardless of whether the EF is normal or abnormal. If the patient with normal EF develops intolerance to physical exertion, dyspnea and congestion, it is necessary to use the term "Diastolic Heart Failure".</p>
      <p>Researchers have asserted that DHF would really be the clinical manifestation of a transient systolic dysfunction, secondary to ischemia or hypertension. To refute this assertion, Baicu and cols. evaluated patients with a diagnosis of DHF and individuals without ventricular dysfunction through LV manometry associated with the calculation of the ventricular volume<sup>12</sup>. All indices of global systolic function and myocardial contractility were preserved in patients with DHF. The authors concluded that, even in the presence of slight alterations in the systolic function, the term DHF is applicable, considering the evident contribution of diastolic dysfunction in the HF condition.</p>
      <p>
        <bold>Epidemiology</bold>
      </p>
      <p>Among patients with the clinical HF syndrome, the prevalence of HFNEF varies broadly in the different studies, from 40% to 71%, with a mean of 56%<sup>13</sup>. This variation is probably due to the definition adopted for the term "preserved systolic function" and the characteristics of the studied population, such as age, ethnicity and prevalence of the female sex. For instance, two studies published 2000, one developed in the North-American population and another in the European population, used three categories of systolic function: preserved, slightly decreased and moderately or severely decreased. However, in the American study, the systolic function was considered preserved when EF <underline>&gt;</underline> 0.50 and corresponded to 24% of the patients<sup>14</sup>; in the European study the EF <underline>&gt;</underline> 0.45 was considered preserved and corresponded to 38% of the patients<sup>15</sup>. Another aspect is the fact that some studies grouped together patients with normal or slightly decreased EF<sup>16</sup>.</p>
      <p>Regarding age, it is known that the prevalence of HFNEF is directly associated with this variable<sup>4</sup>. A population study including individuals older than 45 years described a prevalence of HF of 2.6%. Of these individuals, 41% presented EF &gt; 0.50<sup>17</sup>. Similar results were found in subsequent publications<sup>18-20</sup>. In elderly populations aged 70 or older, the prevalence can reach 50%<sup>21</sup>. Finally, series of patients with HF and a predominance of the female sex can present rates of preserved EF with frequencies as high as 60%<sup>22</sup>.</p>
      <p>
        <bold>Physiopathology</bold>
      </p>
      <p>The ventricular filling in diastole is defined by the physical characteristics of the chamber, which establish the relations between pressure and volume. These physical characteristics are coordinated by the ventricular compliance that describes the ratio between a given variation in volume and its corresponding variation in pressure<sup>23-27</sup>. Although these concepts are applicable to both ventricles, the left ventricle (LV) will be used as reference to facilitate comprehension.</p>
      <p>The compliance must be analyzed, considering a given ventricle, at the end of the diastolic filling, after the atrial contraction, when all active phenomena of diastole are, in theory, complete (<xref ref-type="fig" rid="f1-body3">Figure 1</xref>). At this exact moment of the cardiac cycle, if the ventricle operates under different loading conditions, the points of pressure-volume association show a characteristic curve in the Cartesian plane, typical of an exponential function.</p>
      <fig id="f1-body3">
        <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf01-en.jpg"/></fig>
      <p>The first clinical implication of this characteristic is that in a given ventricle containing little volume, significant additional increases in volume are tolerated, with no pressure variation. However, after a certain limit, small increases in volume would cause significant variations in diastolic pressure. That is, a same ventricle can present variable compliance, depending on the volume at which it operates<sup>25</sup>.</p>
      <p>The second implication is that small ventricles hold lower volumes, whereas large ventricles can contain higher volumes at low pressure. <xref ref-type="fig" rid="f2-body3">Figure 2</xref> shows the schematic diagram of the deviations of the curve of compliance in pathological situations. In concentric hypertrophy, for instance, there are more marked variations of pressure for a given variation of volume, even within the limits considered to be normal. In these cases, the patient shows a tendency to develop venous congestion, even though the EF is preserved. On the other hand, in dilated chambers, when the curve is shifted to the right, the diastolic pressure will reach high values only when there is excess volume. That is what happens in systolic dysfunctions, when the residual volume in the cavity is increased<sup>23,25</sup>.</p>
      <fig id="f2-body3">
        <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf02-en.jpg"/></fig>
      <p>The diastole comprehends four phases: isovolumetric relaxation, rapid ventricular filling, diastasis and atrial contraction. During the isovolumetric relaxation there is no ventricular filling. The phase of rapid filling goes from 70% to 80% of total ventricular filling in normal individuals and depends directly on the atrioventricular pressure gradient. The diastasis is the phase in which the atrial and ventricular pressures are practically the same and the mitral transvalvular flow corresponds to only 5% of the total flow. The diastasis can be understood as the functional reserve that guarantees the ventricular filling, in spite of variations in heart rate. That is, in case of tachycardia, the period to be consumed would be the diastasis. Thus, within certain limits, the filling would not be impaired. The atrial contraction contributes with 15% to 25% of the diastolic volume and, in physiological situations, courses with the maintenance of the mean atrial pressure.</p>
      <p>Within the physiological limits of heart rate variation and considering these four phases of diastole, the factors that affect ventricular compliance and are associated with HFNEF are: myocardial passive stiffness, ventricular geometry, pericardial restraint and interaction between the ventricles.</p>
      <p>
        <bold>Myocardial passive stiffness</bold>
      </p>
      <p>The myocardial passive stiffness also corresponds to a mechanical property and describes the necessary force to be applied to the muscle to produce a given deformity. Thus, according to this physical concept, the myocardium is an inert material, with a physical characteristic that depends intrinsically on its composition and not on the active process of relaxation<sup>27</sup>.</p>
      <p>However, biologically, the altered relaxation can increase the myocardial passive stiffness, as it is not completed. That is, at the end of the diastole, with the muscle still partially contracted, it behaves as a more rigid material. Another relevant aspect is the case of myocardial relaxation that shows only delay. In theory, this alteration should not impair the ventricular compliance, or cause HF. However, if there is tachycardia and diastasis suppression, the slower relaxation can behave as an incomplete relaxation and the ventricular filling will occur at elevated pressure, which can cause congestive phenomena. This is one of the explanations of why patients with HFNEF cannot tolerate increases in heart rate.</p>
      <p>In brief, one can affirm that the myocardial passive stiffness depends on the relaxation and the muscle composition.</p>
      <p>
        <bold>Myocardial relaxation</bold>
      </p>
      <p>The myocardial relaxation requires energy expenditure and starts at the final phase of systolic ejection. This process influences mainly the initial phases of diastole. In normal hearts, even during physical exercise, the process is completed in this period. The release of catecholamines accelerates the relaxation of myocardial fibers, maintaining the low diastolic pressure, in spite of the tachycardia and the increased venous return.</p>
      <p>It is the myocardial relaxation that generates the pressure gradient between the left atrium (LA) and the LV, without an additional increase in the left atrial pressure, preventing pulmonary congestion<sup>24</sup>.</p>
      <p>The relaxation depends mainly on the ATP supply and the intracellular calcium homeostasis. The inadequate function of several proteins involved in calcium homeostasis can also deeply affect the relaxation process<sup>28</sup>.</p>
      <p>In cases of delayed LV relaxation in which there is maintenance of the left atrial pressure, there is a decrease in the atrioventricular pressure gradient and the rapid filling time is prolonged. As a consequence, there is a decrease in the ventricular filling at the initial phase of diastole. At more advanced stages, when in addition to alterations in myocardial relaxation, there is a decrease in ventricular compliance, the pressures in the two chambers, atrium and ventricle, increase, and the patients can present some degree of intolerance to physical exertion. More severe alterations, such as incomplete relaxation and reduced compliance lead to the increase in diastolic pressure to the point of restricting the atrial emptying. In this condition, in general, there are signs that are typical of left HF, such as dyspnea on slight exertion or at rest.</p>
      <p>
        <bold>Myocardial composition</bold>
      </p>
      <p>The myocytes occupy around 70% of the cardiac muscle. In addition to them, there are vessels, fibroblasts and a fibrillar collagen network, with a very complex structure. Although the collagen occupies only 4%-6% of the muscle volume, its high degree of passive stiffness, similar to that of steel, makes small variations in their concentration have significant effects on myocardial passive stiffness<sup>29</sup>.</p>
      <p>In cardiac injuries, the mechanical factors lead to the secondary activation of biochemical factors (neurohormonal activation and release of pro-inflammatory cytokines). Among the several effects of these modifications are: the loss of myocytes, the production of tissue metalloprotease inhibitors by the endothelium and the production of collagen and collagenases by fibroblasts.</p>
      <p>The interaction of these factors determines the concentration of collagen in the myocardial remodeling process.</p>
      <p>Considering the myocardial composition, it is not only the collagen alteration that promotes the diastolic dysfunction. The myocardial hypertrophy is another important variable, which signalizes the evolution of the initial cardiac damage to heart failure and cardiovascular (CV) death. In cases of concentric hypertrophy, there is a decrease in the coronary reserve and increased risk of myocardial ischemia, regardless of the presence of coronary atherosclerotic disease, causing the aforementioned relaxation disorders. The change in the ventricular geometry itself can constitute an independent factor of compliance alteration and diastolic dysfunction<sup>30</sup>.</p>
      <p>
        <bold>Ventricular geometry</bold>
      </p>
      <p>The eccentric hypertrophy (sarcomere multiplication in series) causes the dilatation of ventricular chamber, resulting in higher tolerance to the volume that reaches the ventricles. In this case, the congestive phenomena only appear when the volume inside the chamber exceeds a certain limit. That is, the congestion and the diastolic dysfunction are secondary to the systolic dysfunction. It is important to understand that the dilated ventricle can behave as a compliant chamber, even though the myocardium presents an abnormal concentration of fibrosis and increased passive stiffness.</p>
      <p>The chamber with a concentric geometry has a different behavior because the ventricle is more prone to diastolic dysfunction, regardless of the presence or absence of left ventricular hypertrophy (LVH). From the physical point of view, it is easy to understand that a small-radius chamber with thick walls presents higher resistance to stretching. However, the change in geometry is more complex and extrapolates the physical characteristic. The concentric geometry is associated with significant metabolic changes, functional activation and change in the gene-expression profile of the muscle<sup>31</sup>. All these factors act synergistically to promote myocardial dysfunction.</p>
      <p>
        <bold>Pericardial restraint</bold>
      </p>
      <p>The heart is contained inside a rigid structure consisting of collagen that is the pericardial sac. The pericardium has great capacity to adapt to situations of chronic ventricular dilatation, when there is an increase in compliance.</p>
      <p>In contrast, in situations of acute dilatation of any of the ventricles, as in some cases of mitral regurgitation and cor pulmonale, the increased diastolic pressure and the occasional pulmonary congestion can present a component of the restraint force imposed by the pericardial sac.</p>
      <p>
        <bold>Interaction between the ventricles</bold>
      </p>
      <p>Acute increases in the volume and pressure of one of the ventricles can affect the compliance of the other. However, this interaction is much attenuated in the absence of the pericardium.</p>
      <p>
        <bold>Clinical presentation and diagnosis</bold>
      </p>
      <p>The clinical presentation is similar to that of systolic heart failure. It has been described that, in HFNEF, the establishment of dyspnea presents a more acute onset and that the response to the intervention is equally faster<sup>32,33</sup>. In an European study that included hospitalized patients with HF, it was observed that the prevalence of HFNEF was 40%. This entity was associated significantly and independently with the female sex, advanced age and presence of atrial fibrillation (AF). The systolic heart failure was associated with more advanced functional class (NYHA), cardiomegaly, presence of third sound, acute pulmonary edema and left bundle-branch block<sup>32</sup>. <xref ref-type="fig" rid="c1-body3">Chart 1</xref> shows the differences between HFNEF and HF with decreased EF.</p>
      <fig id="c1-body3">
        <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf03-en.jpg"/></fig>
      <p>The HF secondary to DD is currently understood as the entity of comorbidities. Several studies have shown that patients with HFNEF present systemic arterial hypertension (SAH), myocardial ischemia, diabetes mellitus (DM), obesity and thyroid dysfunction. The association with intrinsic heart diseases is less frequent<sup>34,35</sup>.</p>
      <p>The indices capable of directly quantifying the diastolic function are obtained through invasive procedures. The first one is the tau constant, a broadly used measurement of the rate of LV relaxation<sup>36,37</sup>. The second direct indicator is the measurement of the ventricular compliance, which requires the simultaneous recording of the pressure and volume of the chamber<sup>12</sup>. The less compliant ventricle is the one that presents a higher increase in pressure for a given volume variation. It is clear that neither index can be used routinely in clinical practice.</p>
      <p>The available markers in clinical practice reflect, in fact, a set of variables that indirectly evaluate the diastolic function. Although the most often used indicators for the assessment of diastolic dysfunction are obtained through the echocardiogram, the diagnosis must follow the recommendations of the Brazilian Society of Cardiology for the diagnosis of HF of any etiology<sup>38</sup>. That is, when there is a clinical suspicion of HF, it is necessary to carry out an electrocardiogram, chest X-ray, and, if possible, the BNP measurement. If these laboratory tests show alterations, the echocardiogram is then performed, which will confirm or rule out the diagnosis of HFNEF. It is important to remember that, due to the easy applicability of the examination, the chest X-ray, although not specific, can help to clarify the diagnosis suspicion. That is, when assessing a case of HF, the presence of cardiomegaly increases the chance of systolic dysfunction. On the other hand, is the cardiac area is normal, the probability of HFNEF increases.</p>
      <p>The echocardiogram is more accurate and allows the diagnosis of structural alterations, such as hypertrophy and areas of hypokinesis, frequently associated with diastolic dysfunction. The hypokinesis is strongly suggestive of myocardial ischemia, with the deleterious effects on relaxation explaining the association. Moreover, the pulsed Doppler allows the analysis of the transmitral diastolic flow, which originates the primary function indices and the stratification of the dysfunction severity<sup>39</sup>.</p>
      <p>As described before, this flow depends on the transvalvular pressure gradient. Under normal conditions, this gradient is maximal immediately after the opening of the mitral valve, considering the plenitude of the left atrium volume and the low intraventricular pressure, due to the myocardial relaxation and the small residual volume in the chamber. At this moment, the flow velocity is maximal, which corresponds to the E wave.</p>
      <p>A period of reduced transvalvular gradient follows, with an almost null flow (diastasis). The atrial contraction generates a new gradient and flow, which corresponds to the A wave. The E/A ratio, one of the primary indices for the study of the diastole, remains 1 (<xref ref-type="fig" rid="en_19f3-body3">Figure 3</xref>, <xref ref-type="fig" rid="en_19f3-body3">A</xref>). When the myocardial relaxation is impaired, there is a decrease in the transvalvular gradient in the beginning of diastole, with a decrease in the E wave. The consequence is an impairment in atrial emptying; the atrial contraction is more vigorous and the A wave increases, decreasing the E/A ratio (<xref ref-type="fig" rid="en_19f3-body3">Figure 3</xref>, <xref ref-type="fig" rid="en_19f3-body3">B</xref>). This flow pattern is characteristic of mild or grade I DD. When there is additional functional impairment, the pressure in the left atrium increases, rebuilding the transvalvular pressure gradients during diastole, although at higher pressure levels and in the presence of symptoms of intolerance to physical exertion. At this stage, the DD is grade II, or moderate (<xref ref-type="fig" rid="en_19f3-body3">Figure 3</xref>, <xref ref-type="fig" rid="en_19f3-body3">C</xref>).</p>
      <p content-type="html"><fig id="en_19f3-body3"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/944N6f3NJtJyn9pC7Dnh4yL/2dfe4d2dde3188fc5c22ef0e8b82f340d95876e9.jpg"/><graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf04-en.jpg"/></fig>&#13;
</p>
      <p>In patients in whom the LV diastolic pressure is high enough to restrict the transvalvular flow during the atrial contraction, the elevated LA pressure allows only an initial high-velocity and short-duration diastolic flow, whereas the flow velocity at the end of diastole being markedly decreased (<xref ref-type="fig" rid="en_19f3-body3">Figure 3</xref>, <xref ref-type="fig" rid="en_19f3-body3">D</xref>). This pattern, called restrictive or grade III pattern, is severe and causes intolerance to slight physical exertion. When the Valsalva maneuver does not bring relief to this alteration, the DD grade IV is defined, which is also severe. The other two primary indicators derived from the pulsed Doppler are the time of deceleration of the E wave and the time of isovolumetric relaxation.</p>
      <p>The analysis of the flow in the pulmonary veins through the pulsed Doppler allows the indirect assessment of the atrial pressure, which, in the absence of mitral valvulopathy, corresponds to the LV diastolic pressure. In brief, the normal LA pressures allow a constant flow from the pulmonary veins, except during the atrial contraction, when there is a small reverse flow. When this pattern is altered, it is possible to diagnose diastolic dysfunction.</p>
      <p>More recently, other important indices have been included in the assessment of the diastolic function, such as the measurement of the mitral annular tissue velocity (tissue Doppler) and the estimate of LA volume and emptying fraction. Currently, these variables, together with the assessment of ventricular volume and myocardial mass, are considered fundamental for the definition of the diagnosis and stratification of the severity of HFNEF<sup>15,39</sup>. It is noteworthy that the European, American and Brazilian recommendations on this topic have incorporated the physiological alterations inherent to aging in the values of the primary indices and those derived from tissue Doppler imaging<sup>14,15,38</sup>. Thus, the accuracy of method to identify higher-risk individuals will be improved.</p>
      <p>A relevant aspect to be considered by the clinician that treats patients with HFNEF is the lability of several indices of diastolic function in relation to physical activity. When the examinations are carried out with the patient at rest, there can be a discrepancy between the intensity of the exertional dyspnea and the result of the stratification of the degree of DD. In these cases, the echocardiographic assessment can be carried out immediately after the physical exertion<sup>39</sup>.</p>
      <p>The detailed and technical discussion on these indicators is more attractive for the specialist in echocardiography and is not the focus of the present review. However, it is necessary to reinforce the fact that the reliability of the noninvasive indices, especially the flow velocity/mitral annular tissue velocity ratio, to estimate the LV filling pressure remains debatable in the literature<sup>40-42</sup>.</p>
      <p>The definitive diagnosis of DD requires three criteria, according to the current concept<sup>15</sup>: two major ones and a confirmatory one. The unequivocal evidence of DD and the objective evidence of preserved systolic function (EF &gt; 0.50 during the 72 hours of the acute stage of HF) constitute major criteria. The objective evidence of DHF constitutes a confirmatory criterion. The objective assessment of the DD could be obtained through the echocardiogram, according to Paulus et al<sup>15</sup>, or from an invasive direct measurement, according to Vasan and Levy<sup>43</sup>.</p>
      <p>In 2001, Zile et al<sup>44</sup> evaluated, through cardiac catheterism, the diastolic function of patients with DHF and verified that all of them presented DD. Zile et al<sup>44</sup> questioned the need for this third criterion. In 2005, Yturralde and Gaasch<sup>45</sup> proposed that the two first criteria were considered major ones, as long as the LV size was normal and that the third criterion should be considered only confirmatory, associated to the presence of LVH and increased LA, in the absence of mitral valvulopathy and AF<sup>45</sup>.</p>
      <p>In fact, these indirect signs are being considered more important as DD markers. Pritchett et al<sup>46</sup> used the values of the LA volume in more than 2,000 individuals, aged <underline>&gt;</underline> 45 years, included in the study of the County of Olmsted and observed that this variable had a prognostic value in the prediction of 5-year mortality<sup>46</sup>. Lester and cols. defended the position that the LA volume is for DD as glycated hemoglobin is for DM<sup>47</sup>.</p>
      <p>However, there can be many difficulties in the diagnosis, such as the impossibility to obtain the echocardiogram or unspecific symptoms and little evident signs. The patients often have associated pulmonary disease or are obese; they are elderly individuals with several comorbidities or communication deficit. In conclusion, there are many clinical circumstances that can prevent the direct association between a complaint of physical limitation or dyspnea with a diagnosis of HF.</p>
      <p>In these cases, a laboratory marker that can be useful is the plasma level of BNP (brain natriuretic factor). This natriuretic peptide is stored in the ventricular myocardium, being released when the wall undergoes stretching. It is less influenced by the atrial pressure variations and thus, reflects better the ventricular dysfunction than the atrial natriuretic peptide.</p>
      <p>Many studies have shown the usefulness of BNP as a diagnostic and prognostic marker in systolic HF<sup>48,49</sup>. In diastolic HF, the evidence is not so strong, but they have started to appear. The BNP level with the highest accuracy to detect diastolic dysfunction is 60-90 pg/ml<sup>50</sup>. Additionally, the more severe the dysfunction, the higher the BNP level, which further increases in the presence of clinical signs of HF. The current consensus understands that the BNP level is even more important to rule out the cardiac origin of patients treated for apnea at rest<sup>38</sup>.</p>
      <p>
        <bold>Treatment</bold>
      </p>
      <p>Few studies have assessed the clinical outcomes in patients with DHF that were treated with different classes of drugs. And the fact is that none of them showed a change in the natural history of the syndrome.</p>
      <p>The first large and well-known study was the CHARM-preserved<sup>51</sup>, published in 2003 and aimed at evaluating the effect of candesartan in 3,025 patients with HF and EF &gt; 40%. The study population consisted mainly of male individuals and was at an age range that was younger than the one that most often presents DHF. There was no decrease in mortality in this study, although the number of hospitalizations due to HF was significantly lower.</p>
      <p>The PEP-CHF<sup>52</sup> study included older patients, aged 70 years and older and with EF &gt; 45% and failed to demonstrate a decrease in mortality with the prolonged use of perindopril. Other studies did not show relevant effects of the use of nebivolol<sup>53</sup> and digoxin<sup>54</sup>. Recently, the I PRESERVED study, including patients aged 60 years and older with EF &gt; 60%, demonstrated that the use of irbesartan did not decrease the risk of the compound outcome death and hospitalization due to cardiovascular cause<sup>55</sup>. The TOPCAT study, predicted to finish in 2011, intends to assess the effects of spironolactone on the clinical outcomes of 4,500 patients with preserved systolic function.</p>
      <p>In this context, currently the main objectives in the treatment of HFNEF are: to control symptoms by reducing the venous congestion and heart rate. The rhythm control is also considered valid in selected patients, either by electrical and/or chemical cardioversion or sequential pacemaker.</p>
      <p>Other objectives to be attained are the control of comorbidities associated with DD, such as the treatment of myocardial ischemia and SAH, prevention and reversal of LV hypertrophy, attenuation or prevention of myocardial fibrosis.</p>
      <p>It is necessary to remember that these patients with DD are typically elderly individuals with a normal-sized ventricular cavity. Therefore, drugs such as diuretics and vasodilators can have a disproportional effect on BP. The specific care measures include the monitoring of the BP, kidney function and signs of brain hypoflow. They also include the stimulation to treatment adherence and changes in lifestyle (food ingestion, physical activity and smoking, mainly), considering that these patients are medicated simultaneously with several classes of drugs.</p>
      <p>In elderly patients, the conduct must follow some special criteria. It is advisable to start with a certain drug class and gradually add other classes, always one at a time. There is no evidence that the target-dose of each class must be reached, as it occurs in systolic HF. Therefore, it is recommended:</p>
      <list list-type="bullet">
        <list-item>
          <p>Start diuretics and beta-blockers with caution;</p>
        </list-item>
        <list-item>
          <p> If the HF persists, add an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB), if there is intolerance to ACEI;</p>
        </list-item>
        <list-item>
          <p> Add isosorbide dinitrate and hydralazine, if necessary;</p>
        </list-item>
        <list-item>
          <p> Add calcium-channel antagonists, if necessary;</p>
        </list-item>
        <list-item>
          <p> Avoid the use of digitalis, in the absence of AF.</p>
        </list-item>
      </list>
      <p><xref ref-type="fig" rid="en_19c2-body3">Chart 2</xref> summarizes the main therapeutic options and respective levels of evidence in cases of HFNEF according to the III Brazilian Guidelines on Chronic Heart Failure<sup>38</sup>. Note that the levels of evidence for each therapeutic option are not yet high. Therefore, an individualized treatment is important for these patients.</p>
      <p content-type="asset">
        <fig id="en_19c2-body3">
          <graphic xlink:href="1678-4170-abc-94-05-0694-00019-gf05-en.jpg"/></fig>
      </p>
      <p>
        <bold>Prognosis</bold>
      </p>
      <p>A study with patients with HFNEF showed that 1-year, 3-year and 5-year survival was, respectively, 84%, 67% and 51%<sup>32</sup>. In another study the impact of the severity of DD was assessed in 2,042 adults aged &gt; 45 years, with 95% of them being asymptomatic. It was observed that mortality was significantly higher in those with an echocardiogram result of DD grades II and III<sup>17</sup>.</p>
      <p>These results were similar to the ones described by Pritchett et al<sup>46</sup>. Moreover, these authors observed that the LA volume presented a prognostic value similar to that of DD severity. In patients with chronic coronary failure, the 3-year cardiovascular mortality was significantly higher (6%) in cases with moderate or severe DD, when compared with mild dysfunction (3.6%) or normal diastole (1.1%)<sup>56</sup>.</p>
      <p>Jones et al<sup>34</sup> evaluated the 3-year mortality of a cohort of almost 1,000 patients with HFNEF and EF &gt; 0.45, who participated in the DIG clinical trial. Among the 18 analyzed variables, the ones that associated with death were: glomerular filtration, NYHA functional class, male sex, advanced age, cardiothoracic index, presence of DM, the need for vasodilators or diuretics. Considering these variables, the patients were assigned risk scores and those with the highest scores (75<sup>th</sup> quartile) presented a mortality rate of 50% in the period. Therefore, the patient with HFNEF needs to be assessed through an extensive set of clinical and laboratory variables, which can extrapolate the definition of the degree of dysfunction or of other echocardiographic variables.</p>
      <p>
        <bold>Perspectives</bold>
      </p>
      <p>Finally, an aspect that is once more being discussed in the literature is the question regarding the role of systolic dysfunction in HFNEF. In the study by Yu e cols., that included normal patients and patients with DD or systolic HF, it was demonstrated that the systolic function index assessed by tissue Doppler progressively decreased as the diastolic dysfunction degree worsened. This result suggests that patients with DD also have systolic dysfunction, albeit without clinical manifestations or with preserved EF.</p>
      <p>Another study that used the analysis of ventricular function through the strain rate, identified a direct association between the peak contraction and peak relaxation in normal individuals or with different cardiopathies, suggesting the interdependence of the two phases of the cardiac cycle<sup>58</sup>.</p>
      <p>A more recent study, by Yu et al<sup>59</sup>, analyzed 56 patients with HFNEF and demonstrated that several echocardiographic indices of systolic function, obtained at rest, were significantly lower when compared to 27 healthy individuals<sup>59</sup>. Furthermore, in the group with HFNEF, these indices did not increase at exercise. This study supports the hypothesis that HFNEF is not a disorder that involves diastole alone, even if the EF is preserved. It also supports the assertions by Lester et al<sup>47</sup>: "Perhaps, in a near future, the systolic and diastolic functions will not be clinically interpreted as dichotomous terms. They will be simply understood as cardiac dysfunction".</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
